data_1w7e_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1w7e _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.441 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.481 ' CG2' ' HG ' ' A' ' 39' ' ' LEU . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.612 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.46 HG21 ' HA ' ' A' ' 32' ' ' ALA . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 36' ' ' THR . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.655 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.499 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 67' ' ' PHE . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.655 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.544 ' O ' ' CB ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.482 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.527 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.612 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.449 ' CD1' HG23 ' A' ' 25' ' ' ILE . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.405 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.502 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' CA ' HG13 ' A' ' 149' ' ' ILE . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.539 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.539 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.504 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.504 ' N ' ' HG3' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.497 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.478 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 0.4 OUTLIER -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.502 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.406 ' CB ' HG23 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.497 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.842 0.267 . . . . 0.0 112.222 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 132' ' ' VAL . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.414 ' CG2' ' HB3' ' A' ' 147' ' ' HIS . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.524 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . 0.403 ' CA ' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.441 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' THR . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.524 HG13 ' HB3' ' A' ' 138' ' ' ASP . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . 0.414 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.4 HG13 ' CA ' ' A' ' 62' ' ' PRO . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' MET . . . . . 0.478 ' HG3' ' CG ' ' A' ' 94' ' ' HIS . 5.3 mmt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.408 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.719 ' HB ' ' HB2' ' A' ' 43' ' ' GLU . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.456 ' N ' HG21 ' A' ' 26' ' ' VAL . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.454 HG21 ' HA ' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.651 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HA ' HG21 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.451 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.617 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.556 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.446 ' OG1' ' CE2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.617 ' HB2' ' CB ' ' A' ' 35' ' ' PHE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.651 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.493 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.719 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.705 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.459 ' CG ' ' CG2' ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.532 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.408 HG21 ' CD2' ' A' ' 94' ' ' HIS . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.71 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.446 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.457 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.457 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.429 ' O ' ' HG2' ' A' ' 86' ' ' LYS . 1.9 m120 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.429 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.474 ' HB ' ' CA ' ' A' ' 115' ' ' GLU . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.498 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.408 ' CD2' HG21 ' A' ' 59' ' ' VAL . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.532 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.42 ' CB ' HG23 ' A' ' 58' ' ' THR . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.407 ' O ' ' N ' ' A' ' 106' ' ' THR . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' THR . . . . . 0.407 ' N ' ' O ' ' A' ' 102' ' ' SER . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.498 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 115' ' ' GLU . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.506 ' N ' HG11 ' A' ' 114' ' ' VAL . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 111' ' ' ALA . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 2.5 pt? . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo . . . . . 0 C--O 1.232 0.187 0 CA-C-O 120.762 0.234 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.47 ' O ' ' N ' ' A' ' 129' ' ' VAL . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' A' ' 146' ' ' ILE . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . 0.419 ' HB1' HG12 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.408 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.46 ' CG2' ' HB ' ' A' ' 58' ' ' THR . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.419 HG12 ' HB1' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.71 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.446 HG13 ' HB3' ' A' ' 62' ' ' PRO . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' MET . . . . . 0.426 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 11.3 mtm . . . . . 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.548 ' CD1' ' HB3' ' A' ' 142' ' ' SER . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.787 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.411 ' O ' ' CG2' ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.628 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.411 ' CG2' ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.628 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.542 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.432 ' CG2' HD11 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.466 HD11 ' N ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.628 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.445 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.664 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.535 ' CB ' ' O ' ' A' ' 42' ' ' ALA . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.787 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.408 ' H ' ' CG1' ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.402 ' HG ' ' HG ' ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.558 ' HG2' HG11 ' A' ' 26' ' ' VAL . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.49 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.444 ' CG1' ' CD2' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.448 ' CE2' ' CD2' ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.448 ' CD2' ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.466 ' HA ' ' CE1' ' A' ' 94' ' ' HIS . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.409 ' HB ' ' CB ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.512 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.466 ' CE1' ' HA ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.451 ' N ' ' O ' ' A' ' 91' ' ' LEU . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.49 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.512 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.409 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 127' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' HA ' ' A' ' 123' ' ' LEU . 60.6 Cg_endo . . . . . 0 C--O 1.232 0.221 0 CA-C-O 120.814 0.256 . . . . 0.0 112.37 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 120' ' ' THR . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 129' ' ' VAL . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . 0.419 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.407 ' CB ' ' CG2' ' A' ' 146' ' ' ILE . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . 0.408 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.559 ' C ' ' H ' ' A' ' 144' ' ' GLY . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.497 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 5.6 t-20 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.559 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.408 HG23 ' HB2' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.403 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.507 ' O ' ' HB ' ' A' ' 28' ' ' THR . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.58 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 35' ' ' PHE . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.774 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.56 ' HB2' ' CG2' ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.532 ' O ' ' CG2' ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.435 HG23 ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.575 ' O ' ' HB1' ' A' ' 42' ' ' ALA . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.774 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.575 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HB3' ' HB1' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.452 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.58 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.407 ' H ' ' CG1' ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.448 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.41 ' CD ' ' ND2' ' A' ' 143' ' ' ASN . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.543 ' HA2' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.543 ' CE2' ' HA2' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.479 ' HB ' ' HB ' ' A' ' 145' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG1' ' CD2' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.455 ' HB2' ' CD1' ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.418 ' CG2' HG12 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.462 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.462 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.407 ' ND2' ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.445 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.414 ' HG ' HG22 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.537 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.438 ' CD2' ' CG1' ' A' ' 59' ' ' VAL . 1.5 p-80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.431 HG21 ' CD2' ' A' ' 94' ' ' HIS . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.46 HG11 HG21 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.537 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 130' ' ' ASN . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo . . . . . 0 C--O 1.232 0.189 0 CA-C-O 120.922 0.301 . . . . 0.0 112.337 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 120' ' ' THR . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 119' ' ' LEU . 4.4 t30 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.52 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.401 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.41 ' ND2' ' CD ' ' A' ' 52' ' ' LYS . 53.6 t30 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 58' ' ' THR . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.576 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 62' ' ' PRO . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.455 ' CD1' ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' MET . . . . . 0.458 ' O ' ' CG ' ' A' ' 93' ' ' TYR . 13.5 ptm . . . . . 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.523 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.431 ' CD1' ' HE2' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.507 ' O ' ' N ' ' A' ' 32' ' ' ALA . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.616 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.507 ' N ' ' O ' ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.561 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' THR . . . . . 0.427 ' OG1' ' CD2' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.561 ' HB2' ' CB ' ' A' ' 35' ' ' PHE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.616 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 40' ' ' THR . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.793 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.774 ' HG2' HG13 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.793 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.68 ' HA ' HG13 ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.452 ' C ' ' HD2' ' A' ' 52' ' ' LYS . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.673 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . 0.449 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.434 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.421 HG11 ' CD2' ' A' ' 94' ' ' HIS . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.586 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.463 ' HB3' HG13 ' A' ' 149' ' ' ILE . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.406 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.518 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.466 ' O ' ' HG2' ' A' ' 86' ' ' LYS . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.43 ' CG2' ' HB3' ' A' ' 93' ' ' TYR . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.449 ' O ' ' CG2' ' A' ' 95' ' ' VAL . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 115' ' ' GLU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.43 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.421 ' CD2' HG11 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 91' ' ' LEU . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.426 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.417 ' HB2' HG23 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.408 ' HB3' ' CD1' ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.423 HG23 ' CD1' ' A' ' 93' ' ' TYR . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . 0.408 ' CD1' ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.805 0.252 . . . . 0.0 112.24 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 120' ' ' THR . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.444 ' O ' ' C ' ' A' ' 135' ' ' SER . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . 0.42 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . 0.407 ' CA ' HG12 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.523 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.489 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.449 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 58' ' ' THR . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . 0.421 ' N ' HG11 ' A' ' 145' ' ' VAL . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.463 HG13 ' HB3' ' A' ' 62' ' ' PRO . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . 0.405 ' CD1' HG23 ' A' ' 132' ' ' VAL . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' MET . . . . . 0.407 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 2.4 mtm . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.507 ' H ' ' HG3' ' A' ' 52' ' ' LYS . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.544 ' HA ' ' CD2' ' A' ' 39' ' ' LEU . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.623 ' CG2' ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.481 ' O ' ' N ' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . 0.481 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.781 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.539 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.443 HD21 ' CE1' ' A' ' 67' ' ' PHE . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.781 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.52 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.567 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.557 ' CB ' ' O ' ' A' ' 42' ' ' ALA . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.623 ' HA ' ' CG2' ' A' ' 26' ' ' VAL . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.429 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' LYS . . . . . 0.507 ' HG3' ' H ' ' A' ' 24' ' ' ASP . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.404 ' H ' ' HA2' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . 0.446 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ALA . . . . . 0.584 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PHE . . . . . 0.55 ' CD2' ' HB3' ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LEU . . . . . 0.55 ' HB3' ' CD2' ' A' ' 67' ' ' PHE . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LYS . . . . . 0.444 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.414 ' O ' ' CD2' ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.418 ' HG2' ' HA ' ' A' ' 86' ' ' LYS . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ILE . . . . . 0.451 ' O ' ' CG2' ' A' ' 90' ' ' ILE . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.421 ' HA ' ' CE1' ' A' ' 94' ' ' HIS . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' THR . . . . . 0.444 ' CB ' ' HB2' ' A' ' 115' ' ' GLU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . 0.447 ' O ' ' CG2' ' A' ' 113' ' ' THR . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' HIS . . . . . 0.448 ' CE1' HG21 ' A' ' 95' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.448 HG21 ' CE1' ' A' ' 94' ' ' HIS . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.446 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.43 ' CB ' HG23 ' A' ' 58' ' ' THR . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.413 ' CG2' ' CD2' ' A' ' 105' ' ' LEU . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.413 ' CD2' ' CG2' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.447 ' CG2' ' O ' ' A' ' 93' ' ' TYR . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . 0.444 ' HB2' ' CB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.978 0.324 . . . . 0.0 112.395 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 120' ' ' THR . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' ILE . . . . . 0.483 ' CG2' ' HB3' ' A' ' 137' ' ' PRO . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' PRO . . . . . 0.483 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.506 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLY . . . . . 0.404 ' HA2' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.412 ' CG2' ' HB ' ' A' ' 58' ' ' THR . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' HIS . . . . . 0.41 ' HA ' ' CB ' ' A' ' 137' ' ' PRO . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.584 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.441 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.481 ' CG2' ' HG ' ' A' ' 39' ' ' LEU . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.612 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.46 HG21 ' HA ' ' A' ' 32' ' ' ALA . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 36' ' ' THR . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.655 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.499 ' HA ' ' HB1' ' A' ' 32' ' ' ALA . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.496 ' HB2' ' CZ ' ' A' ' 67' ' ' PHE . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.655 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.544 ' O ' ' CB ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.482 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.568 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.568 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.527 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.612 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.449 ' CD1' HG23 ' A' ' 25' ' ' ILE . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.405 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.502 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' CA ' HG13 ' A' ' 149' ' ' ILE . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.539 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.539 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.504 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.504 ' N ' ' HG3' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.497 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.429 ' CD2' ' HD3' ' A' ' 155' ' ' PRO . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.478 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 0.4 OUTLIER -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.502 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.406 ' CB ' HG23 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.497 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.406 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -122.18 -65.15 1.14 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -61.29 153.17 27.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.0 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 60.25 24.7 61.5 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.676 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 114.37 101.35 2.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.526 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.36 131.09 23.93 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.433 2.088 . . . . 0.0 112.222 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 132' ' ' VAL . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.414 ' CG2' ' HB3' ' A' ' 147' ' ' HIS . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.524 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . 0.403 ' CA ' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.441 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.405 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 58' ' ' THR . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.524 HG13 ' HB3' ' A' ' 138' ' ' ASP . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . 0.414 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.4 HG13 ' CA ' ' A' ' 62' ' ' PRO . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' MET . . . . . 0.478 ' HG3' ' CG ' ' A' ' 94' ' ' HIS . 5.3 mmt 59.18 157.67 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 1.482 ' C ' ' H ' ' A' ' 156' ' ' GLY . 60.8 Cg_endo -71.92 148.14 50.99 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.721 2.28 . . . . 0.0 112.402 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 1.482 ' H ' ' C ' ' A' ' 155' ' ' PRO . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.408 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.719 ' HB ' ' HB2' ' A' ' 43' ' ' GLU . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.456 ' N ' HG21 ' A' ' 26' ' ' VAL . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.454 HG21 ' HA ' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.651 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.454 ' HA ' HG21 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.451 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.617 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.556 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.446 ' OG1' ' CE2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.617 ' HB2' ' CB ' ' A' ' 35' ' ' PHE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.651 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.493 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.719 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.467 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.705 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.459 ' CG ' ' CG2' ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.532 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.408 HG21 ' CD2' ' A' ' 94' ' ' HIS . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.71 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.446 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.457 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.457 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.429 ' O ' ' HG2' ' A' ' 86' ' ' LYS . 1.9 m120 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.429 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.474 ' HB ' ' CA ' ' A' ' 115' ' ' GLU . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.498 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.408 ' CD2' HG21 ' A' ' 59' ' ' VAL . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.532 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.42 ' CB ' HG23 ' A' ' 58' ' ' THR . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.407 ' O ' ' N ' ' A' ' 106' ' ' THR . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' THR . . . . . 0.407 ' N ' ' O ' ' A' ' 102' ' ' SER . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.498 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.506 HG11 ' N ' ' A' ' 115' ' ' GLU . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.506 ' N ' HG11 ' A' ' 114' ' ' VAL . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 111' ' ' ALA . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.419 ' HG ' ' N ' ' A' ' 124' ' ' GLU . 2.5 pt? -130.04 -41.91 1.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.419 ' N ' ' HG ' ' A' ' 123' ' ' LEU . 12.5 tt0 -95.1 152.83 18.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.925 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 67.21 25.53 73.5 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.549 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 123.76 78.29 0.39 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.45 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -49.74 122.03 8.26 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.586 2.191 . . . . 0.0 112.266 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.47 ' N ' ' O ' ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.47 ' O ' ' N ' ' A' ' 129' ' ' VAL . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' A' ' 146' ' ' ILE . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . 0.419 ' HB1' HG12 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.408 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.46 ' CG2' ' HB ' ' A' ' 58' ' ' THR . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.419 HG12 ' HB1' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.71 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.446 HG13 ' HB3' ' A' ' 62' ' ' PRO . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' MET . . . . . 0.426 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 11.3 mtm 72.47 148.03 0.12 Allowed Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 0.407 ' HG2' ' CG2' ' A' ' 90' ' ' ILE . 10.3 Cg_endo -51.72 -24.62 18.39 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.82 2.347 . . . . 0.0 112.345 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.406 ' N ' HG12 ' A' ' 90' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.393 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.364 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.548 ' CD1' ' HB3' ' A' ' 142' ' ' SER . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.787 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.411 ' O ' ' CG2' ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.522 ' O ' ' N ' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.628 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.411 ' CG2' ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.628 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.542 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.432 ' CG2' HD11 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.466 HD11 ' N ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.628 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.445 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.664 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.535 ' CB ' ' O ' ' A' ' 42' ' ' ALA . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.787 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' H ' ' CG1' ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.402 ' HG ' ' HG ' ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.558 ' HG2' HG11 ' A' ' 26' ' ' VAL . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.49 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.444 ' CG1' ' CD2' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.448 ' CE2' ' CD2' ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.448 ' CD2' ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . . . . . . . . . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.466 ' HA ' ' CE1' ' A' ' 94' ' ' HIS . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.409 ' HB ' ' CB ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.512 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.466 ' CE1' ' HA ' ' A' ' 91' ' ' LEU . 1.0 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.451 ' N ' ' O ' ' A' ' 91' ' ' LEU . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.49 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.512 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.409 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.511 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 127' ' ' PRO . 0.3 OUTLIER -155.98 -39.12 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 7.3 tt0 -63.82 126.73 28.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.382 . . . . 0.0 111.202 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.88 33.69 86.26 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.898 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 112.56 107.05 2.85 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.512 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.421 ' HA ' ' HA ' ' A' ' 123' ' ' LEU . 60.6 Cg_endo -71.88 150.09 54.75 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.499 2.133 . . . . 0.0 112.37 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 120' ' ' THR . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.472 ' O ' ' N ' ' A' ' 129' ' ' VAL . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . 0.419 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.407 ' CB ' ' CG2' ' A' ' 146' ' ' ILE . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . 0.408 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.559 ' C ' ' H ' ' A' ' 144' ' ' GLY . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.497 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 5.6 t-20 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.559 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.408 HG23 ' HB2' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER 62.21 157.16 0.12 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -51.68 -24.4 17.6 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.916 2.411 . . . . 0.0 112.519 -179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.646 179.812 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.403 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.507 ' O ' ' HB ' ' A' ' 28' ' ' THR . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.58 ' CG1' ' HA ' ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 35' ' ' PHE . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.774 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.56 ' HB2' ' CG2' ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.532 ' O ' ' CG2' ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.435 HG23 ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.575 ' O ' ' HB1' ' A' ' 42' ' ' ALA . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.774 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.575 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HB3' ' HB1' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.411 ' HB1' ' O ' ' A' ' 40' ' ' THR . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.452 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.58 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.407 ' H ' ' CG1' ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.448 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.41 ' CD ' ' ND2' ' A' ' 143' ' ' ASN . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.543 ' HA2' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.543 ' CE2' ' HA2' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.479 ' HB ' ' HB ' ' A' ' 145' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.438 ' CG1' ' CD2' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.455 ' HB2' ' CD1' ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.418 ' CG2' HG12 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.462 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.462 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.407 ' ND2' ' HA ' ' A' ' 78' ' ' LEU . 0.9 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.407 ' O ' ' N ' ' A' ' 91' ' ' LEU . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.445 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.466 ' CG2' ' HB3' ' A' ' 155' ' ' PRO . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.414 ' HG ' HG22 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.537 ' HA ' ' HB ' ' A' ' 113' ' ' THR . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.438 ' CD2' ' CG1' ' A' ' 59' ' ' VAL . 1.5 p-80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.431 HG21 ' CD2' ' A' ' 94' ' ' HIS . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.46 HG11 HG21 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.537 ' HB ' ' HA ' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . 0.474 ' HB2' ' HB2' ' A' ' 130' ' ' ASN . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -141.59 -170.18 3.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 63.05 124.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.988 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 66.16 30.17 76.34 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 107.59 92.86 2.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.04 133.69 29.68 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.485 2.124 . . . . 0.0 112.337 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 120' ' ' THR . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 119' ' ' LEU . 4.4 t30 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.52 ' HA ' ' O ' ' A' ' 148' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.401 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.41 ' ND2' ' CD ' ' A' ' 52' ' ' LYS . 53.6 t30 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . . . . . . . . . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.479 ' HB ' ' HB ' ' A' ' 58' ' ' THR . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.576 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.522 ' O ' ' HA ' ' A' ' 62' ' ' PRO . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.455 ' CD1' ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' MET . . . . . 0.458 ' O ' ' CG ' ' A' ' 93' ' ' TYR . 13.5 ptm -141.55 158.02 64.16 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 0.466 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 44.2 Cg_endo -90.39 -17.32 1.5 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 123.017 2.478 . . . . 0.0 112.452 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . 0.424 ' HA3' ' CE2' ' A' ' 93' ' ' TYR . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.508 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.523 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.431 ' CD1' ' HE2' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.507 ' O ' ' N ' ' A' ' 32' ' ' ALA . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.616 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.507 ' N ' ' O ' ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.561 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.427 ' OG1' ' CD2' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.561 ' HB2' ' CB ' ' A' ' 35' ' ' PHE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.616 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.423 ' N ' HG21 ' A' ' 40' ' ' THR . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.793 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.774 ' HG2' HG13 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.793 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.68 ' HA ' HG13 ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.452 ' C ' ' HD2' ' A' ' 52' ' ' LYS . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.673 ' HB2' ' CG1' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . 0.449 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.434 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.421 HG11 ' CD2' ' A' ' 94' ' ' HIS . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.586 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.463 ' HB3' HG13 ' A' ' 149' ' ' ILE . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.518 ' CE2' ' HB3' ' A' ' 78' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.406 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.518 ' HB3' ' CE2' ' A' ' 67' ' ' PHE . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.466 ' O ' ' HG2' ' A' ' 86' ' ' LYS . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.568 HG22 ' HD2' ' A' ' 155' ' ' PRO . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.449 ' O ' ' CG2' ' A' ' 95' ' ' VAL . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.423 ' HB ' ' HB2' ' A' ' 115' ' ' GLU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.43 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.421 ' CD2' HG11 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 91' ' ' LEU . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.426 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.417 ' HB2' HG23 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.408 ' HB3' ' CD1' ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.423 HG23 ' CD1' ' A' ' 93' ' ' TYR . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.423 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.445 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . 0.408 ' CD1' ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER -135.13 -165.24 1.64 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 67.57 124.93 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.086 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.48 26.88 67.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.621 179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 115.53 103.11 2.4 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.454 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.41 138.23 45.61 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.312 2.008 . . . . 0.0 112.24 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 120' ' ' THR . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.444 ' O ' ' C ' ' A' ' 135' ' ' SER . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . 0.42 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . 0.407 ' CA ' HG12 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.523 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.489 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.449 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 58' ' ' THR . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . 0.421 ' N ' HG11 ' A' ' 145' ' ' VAL . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . . . . . . . . . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.463 HG13 ' HB3' ' A' ' 62' ' ' PRO . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . 0.405 ' CD1' HG23 ' A' ' 132' ' ' VAL . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' MET . . . . . 0.407 ' HB3' ' CG2' ' A' ' 90' ' ' ILE . 2.4 mtm 62.33 148.37 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 0.568 ' HD2' HG22 ' A' ' 90' ' ' ILE . 11.2 Cg_endo -52.86 157.1 8.35 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.951 2.434 . . . . 0.0 112.338 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.507 ' H ' ' HG3' ' A' ' 52' ' ' LYS . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.544 ' HA ' ' CD2' ' A' ' 39' ' ' LEU . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.623 ' CG2' ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.481 ' O ' ' N ' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.481 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.781 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.539 ' HA ' ' HB ' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.443 HD21 ' CE1' ' A' ' 67' ' ' PHE . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.781 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.52 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.567 ' HB1' ' O ' ' A' ' 39' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.584 ' O ' HG21 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.557 ' CB ' ' O ' ' A' ' 42' ' ' ALA . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.623 ' HA ' ' CG2' ' A' ' 26' ' ' VAL . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA2' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.429 ' O ' ' HE2' ' A' ' 52' ' ' LYS . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.507 ' HG3' ' H ' ' A' ' 24' ' ' ASP . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.404 ' H ' ' HA2' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . 0.446 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . 0.584 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PHE . . . . . 0.55 ' CD2' ' HB3' ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.55 ' HB3' ' CD2' ' A' ' 67' ' ' PHE . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LYS . . . . . 0.444 ' N ' ' OD1' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . 0.418 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.414 ' O ' ' CD2' ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.418 ' HG2' ' HA ' ' A' ' 86' ' ' LYS . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ILE . . . . . 0.451 ' O ' ' CG2' ' A' ' 90' ' ' ILE . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.421 ' HA ' ' CE1' ' A' ' 94' ' ' HIS . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' THR . . . . . 0.444 ' CB ' ' HB2' ' A' ' 115' ' ' GLU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . 0.474 ' CD2' ' HD2' ' A' ' 155' ' ' PRO . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' HIS . . . . . 0.448 ' CE1' HG21 ' A' ' 95' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.448 HG21 ' CE1' ' A' ' 94' ' ' HIS . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.446 ' HB ' ' CG2' ' A' ' 58' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.43 ' CB ' HG23 ' A' ' 58' ' ' THR . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.413 ' CG2' ' CD2' ' A' ' 105' ' ' LEU . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.413 ' CD2' ' CG2' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.447 ' CG2' ' O ' ' A' ' 93' ' ' TYR . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . 0.444 ' HB2' ' CB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -132.93 -54.62 0.93 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.01 132.72 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.067 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 87.29 -50.25 4.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.482 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -154.44 81.56 0.17 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.064 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -61.95 112.23 1.45 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.601 2.201 . . . . 0.0 112.395 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 120' ' ' THR . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ILE . . . . . 0.483 ' CG2' ' HB3' ' A' ' 137' ' ' PRO . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' PRO . . . . . 0.483 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . . . . . . . . . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ALA . . . . . . . . . . . . . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.506 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLY . . . . . 0.404 ' HA2' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.412 ' CG2' ' HB ' ' A' ' 58' ' ' THR . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' HIS . . . . . 0.41 ' HA ' ' CB ' ' A' ' 137' ' ' PRO . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.584 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER 66.68 145.2 0.1 OUTLIER Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' PRO . . . . . 0.474 ' HD2' ' CD2' ' A' ' 93' ' ' TYR . 5.0 Cg_endo -48.32 149.62 6.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.822 2.348 . . . . 0.0 112.333 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.23 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.541 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.855 HG12 HG21 ' A' ' 59' ' ' VAL . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.623 ' HB ' HG13 ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.731 HG21 ' HB2' ' A' ' 35' ' ' PHE . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 31' ' ' GLY . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.731 ' HB2' HG21 ' A' ' 28' ' ' THR . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.52 ' O ' HG21 ' A' ' 40' ' ' THR . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.532 HG21 ' CG ' ' A' ' 67' ' ' PHE . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.658 HD21 HD13 ' A' ' 87' ' ' LEU . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.82 ' HG ' HG23 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.585 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.827 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.637 ' HG3' HG22 ' A' ' 48' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.827 HD12 ' HA ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.637 HG22 ' HG3' ' A' ' 43' ' ' GLU . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.824 HD12 ' HB1' ' A' ' 42' ' ' ALA . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.408 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.645 HG21 ' CD ' ' A' ' 99' ' ' GLU . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.855 HG21 HG12 ' A' ' 25' ' ' ILE . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 61' ' ' ALA . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.736 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.855 ' CE2' HD22 ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.767 HD12 HD12 ' A' ' 78' ' ' LEU . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.855 HD22 ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.549 ' HG2' ' HB1' ' A' ' 41' ' ' ALA . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.651 ' O ' HD13 ' A' ' 90' ' ' ILE . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.658 HD13 HD21 ' A' ' 38' ' ' LEU . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.666 ' O ' HD22 ' A' ' 91' ' ' LEU . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.651 HD13 ' O ' ' A' ' 86' ' ' LYS . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.782 ' O ' HG23 ' A' ' 95' ' ' VAL . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.517 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.409 ' N ' ' HB2' ' A' ' 115' ' ' GLU . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.485 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 2.4 t-160 -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 91' ' ' LEU . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.719 HG22 ' HA ' ' A' ' 113' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD3' ' CG2' ' A' ' 114' ' ' VAL . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.645 ' CD ' HG21 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.614 HG13 HD21 ' A' ' 105' ' ' LEU . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' MET . . . . . 0.725 ' HE3' HD21 ' A' ' 123' ' ' LEU . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.763 ' HB2' HD11 ' A' ' 123' ' ' LEU . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASP . . . . . 0.546 ' HB3' HD23 ' A' ' 105' ' ' LEU . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.614 HD21 HG13 ' A' ' 100' ' ' VAL . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.516 ' HA ' HD13 ' A' ' 123' ' ' LEU . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.41 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.719 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 95' ' ' VAL . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.517 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.501 HD23 ' HB2' ' A' ' 130' ' ' ASN . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.525 ' O ' HG23 ' A' ' 120' ' ' THR . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.468 ' CG1' ' HE1' ' A' ' 101' ' ' MET . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.763 HD11 ' HB2' ' A' ' 102' ' ' SER . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.842 0.267 . . . . 0.0 112.222 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.842 HG21 HD11 ' A' ' 134' ' ' ILE . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASN . . . . . 0.501 ' HB2' HD23 ' A' ' 119' ' ' LEU . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 0.842 HD11 HG21 ' A' ' 129' ' ' VAL . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.838 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.547 ' HB2' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.459 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.473 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 139' ' ' VAL . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.547 HG12 ' HB2' ' A' ' 141' ' ' ALA . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HG21 ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.736 HG11 HG23 ' A' ' 63' ' ' THR . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.764 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.631 ' HG ' HG21 ' A' ' 132' ' ' VAL . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' MET . . . . . 0.489 ' HE2' HD13 ' A' ' 153' ' ' LEU . 5.3 mmt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.93 ' CG2' HD22 ' A' ' 39' ' ' LEU . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.867 HG21 ' CG ' ' A' ' 52' ' ' LYS . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.406 ' CG ' ' O ' ' A' ' 24' ' ' ASP . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.913 HG22 ' HB2' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.694 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.913 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' CD2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.645 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.93 HD22 ' CG2' ' A' ' 25' ' ' ILE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.694 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.646 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.713 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.619 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 91' ' ' LEU . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.804 ' HA ' HG11 ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.586 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.867 ' CG ' HG21 ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.414 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.545 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.445 ' HB3' HG23 ' A' ' 149' ' ' ILE . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.7 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.418 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.525 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.685 ' CE2' HD22 ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.84 HD21 HG13 ' A' ' 152' ' ' VAL . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.456 HG22 HD13 ' A' ' 70' ' ' LEU . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.477 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.685 HD22 ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.449 ' HA ' ' HG2' ' A' ' 84' ' ' LYS . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 77' ' ' ASP . 1.3 m-80 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.669 ' O ' HD12 ' A' ' 90' ' ' ILE . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.681 ' O ' HG22 ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 47' ' ' LEU . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.877 ' O ' HG12 ' A' ' 114' ' ' VAL . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.471 ' HA ' ' CB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.868 HG22 ' HA ' ' A' ' 113' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.448 ' CG1' HD23 ' A' ' 105' ' ' LEU . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' MET . . . . . 0.426 ' HE3' ' H ' ' A' ' 102' ' ' SER . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.665 ' HB3' HD22 ' A' ' 123' ' ' LEU . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.592 HD12 ' N ' ' A' ' 106' ' ' THR . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.592 ' N ' HD12 ' A' ' 105' ' ' LEU . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.409 ' HB2' HG21 ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 96' ' ' VAL . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.868 ' HA ' HG22 ' A' ' 96' ' ' VAL . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.877 HG12 ' O ' ' A' ' 92' ' ' THR . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.457 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.662 ' O ' HG23 ' A' ' 113' ' ' THR . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.523 HD13 ' HB2' ' A' ' 130' ' ' ASN . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.506 HG12 ' OG ' ' A' ' 102' ' ' SER . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.69 ' H ' HD23 ' A' ' 123' ' ' LEU . 2.5 pt? . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo . . . . . 0 C--O 1.232 0.187 0 CA-C-O 120.762 0.234 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASN . . . . . 0.523 ' HB2' HD13 ' A' ' 119' ' ' LEU . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.876 HG21 ' HB ' ' A' ' 149' ' ' ILE . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 0.601 HD12 HG21 ' A' ' 129' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' PRO . . . . . 0.662 ' O ' HG23 ' A' ' 139' ' ' VAL . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.733 ' O ' HG12 ' A' ' 145' ' ' VAL . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.601 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 139' ' ' VAL . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.601 HG23 ' HB2' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.406 ' O ' ' HA ' ' A' ' 60' ' ' PHE . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.7 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.876 ' HB ' HG21 ' A' ' 132' ' ' VAL . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.793 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.84 HG13 HD21 ' A' ' 70' ' ' LEU . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.794 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 154' ' ' MET . . . . . 0.582 ' HB3' HG21 ' A' ' 90' ' ' ILE . 11.3 mtm . . . . . 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.984 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.944 HG22 ' HG3' ' A' ' 52' ' ' LYS . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.739 ' O ' HG22 ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.969 HG22 ' HB2' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.739 HG22 ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.969 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.669 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.538 ' O ' HG21 ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.664 HG23 HD12 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.904 HD22 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.904 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.511 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.808 HD23 ' CD1' ' A' ' 51' ' ' LEU . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.794 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.647 ' H ' HG13 ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.808 ' CD1' HD23 ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.984 ' CE ' HD12 ' A' ' 25' ' ' ILE . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.505 ' HB ' HG23 ' A' ' 145' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.714 HG13 ' ND1' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.548 ' HB3' HD11 ' A' ' 149' ' ' ILE . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.503 ' HB1' HD21 ' A' ' 38' ' ' LEU . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.542 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.912 ' CE2' HD22 ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.482 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 152' ' ' VAL . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 68' ' ' ALA . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.912 HD22 ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.501 ' ND2' HD23 ' A' ' 78' ' ' LEU . 10.0 t30 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.604 ' O ' HG22 ' A' ' 88' ' ' THR . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.768 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.451 HD12 ' CB ' ' A' ' 154' ' ' MET . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.768 HD22 ' O ' ' A' ' 88' ' ' THR . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.554 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.595 ' CE1' HD21 ' A' ' 119' ' ' LEU . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.714 ' ND1' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.754 ' O ' HG23 ' A' ' 114' ' ' VAL . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 113' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' MET . . . . . 0.533 ' HE2' HG12 ' A' ' 121' ' ' VAL . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' SER . . . . . 0.518 ' C ' HD21 ' A' ' 123' ' ' LEU . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.464 HD12 ' OG1' ' A' ' 106' ' ' THR . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.464 ' OG1' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.627 ' HA ' HG22 ' A' ' 96' ' ' VAL . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 95' ' ' VAL . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.406 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.533 ' O ' HG23 ' A' ' 113' ' ' THR . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.595 HD21 ' CE1' ' A' ' 93' ' ' TYR . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.533 HG12 ' HE2' ' A' ' 101' ' ' MET . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.518 HD21 ' C ' ' A' ' 103' ' ' SER . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo . . . . . 0 C--O 1.232 0.221 0 CA-C-O 120.814 0.256 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.64 HG21 HD12 ' A' ' 153' ' ' LEU . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.478 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' PRO . . . . . 0.506 ' O ' HG23 ' A' ' 139' ' ' VAL . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.495 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.663 ' O ' HG12 ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.483 ' HB3' ' HB ' ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.752 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.514 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.54 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.483 ' HB ' ' HB3' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.47 ' HB3' HG21 ' A' ' 134' ' ' ILE . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.542 HG11 HG23 ' A' ' 63' ' ' THR . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.581 HD13 HD13 ' A' ' 153' ' ' LEU . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.581 ' H ' HG22 ' A' ' 149' ' ' ILE . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 70' ' ' LEU . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.64 HD12 HG21 ' A' ' 132' ' ' VAL . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 154' ' ' MET . . . . . 0.451 ' CB ' HD12 ' A' ' 90' ' ' ILE . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.416 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.923 ' CG2' HD22 ' A' ' 39' ' ' LEU . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.858 ' HB ' HG23 ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . 1.019 HG22 ' HB2' ' A' ' 32' ' ' ALA . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.821 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 1.019 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.535 ' O ' HG21 ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.419 ' CG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.773 HD21 ' HG ' ' A' ' 87' ' ' LEU . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.923 HD22 ' CG2' ' A' ' 25' ' ' ILE . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.821 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.982 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.858 HG23 ' HB ' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.6 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.982 HD12 ' HB1' ' A' ' 42' ' ' ALA . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.554 ' HA3' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.554 ' CE2' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . 1.047 HG23 HG13 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.539 HG13 ' ND1' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.824 ' HB2' HD11 ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 39' ' ' LEU . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.848 HG23 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.726 ' CE2' HD23 ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.585 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.694 HD12 HD22 ' A' ' 78' ' ' LEU . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.585 HG21 ' HA ' ' A' ' 68' ' ' ALA . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.726 HD23 ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 77' ' ' ASP . 0.6 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.795 HD13 HD11 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.795 HD11 HD13 ' A' ' 87' ' ' LEU . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.687 ' CD2' HG21 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.831 ' OH ' HD12 ' A' ' 119' ' ' LEU . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.606 ' CD2' ' HA ' ' A' ' 91' ' ' LEU . 1.3 p80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.723 ' O ' HG23 ' A' ' 114' ' ' VAL . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 1.047 HG13 HG23 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.449 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.409 HG12 ' HB3' ' A' ' 104' ' ' ASP . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' MET . . . . . 0.458 ' HE3' ' H ' ' A' ' 102' ' ' SER . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.655 ' HB3' HD11 ' A' ' 123' ' ' LEU . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 100' ' ' VAL . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.435 ' CG ' HD13 ' A' ' 123' ' ' LEU . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ALA . . . . . 0.952 ' HB3' HD21 ' A' ' 119' ' ' LEU . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.75 HG21 ' CD2' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 95' ' ' VAL . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 113' ' ' THR . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 111' ' ' ALA . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.952 HD21 ' HB3' ' A' ' 111' ' ' ALA . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.655 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo . . . . . 0 C--O 1.232 0.189 0 CA-C-O 120.922 0.301 . . . . 0.0 112.337 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.755 HG21 HD11 ' A' ' 134' ' ' ILE . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASN . . . . . 0.519 ' O ' HG23 ' A' ' 132' ' ' VAL . 1.9 t-20 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.53 HG11 HG22 ' A' ' 149' ' ' ILE . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' SER . . . . . 0.425 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 0.755 HD11 HG21 ' A' ' 129' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.816 ' O ' HG13 ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.568 ' HB2' ' HB ' ' A' ' 146' ' ' ILE . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.406 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.416 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 6.5 t-20 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.411 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 139' ' ' VAL . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.702 HD13 ' N ' ' A' ' 147' ' ' HIS . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.702 ' N ' HD13 ' A' ' 146' ' ' ILE . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.848 HG11 HG23 ' A' ' 63' ' ' THR . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.683 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLY . . . . . 0.683 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.58 HG23 HD21 ' A' ' 70' ' ' LEU . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.824 HD11 ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' MET . . . . . 0.461 ' HG3' ' CZ ' ' A' ' 93' ' ' TYR . 13.5 ptm . . . . . 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.871 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.817 HG12 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.835 HG21 ' HB2' ' A' ' 35' ' ' PHE . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.799 ' HA ' HG23 ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.835 ' HB2' HG21 ' A' ' 28' ' ' THR . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' THR . . . . . 0.492 HG21 ' CG ' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.631 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.8 HD22 ' CG2' ' A' ' 25' ' ' ILE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.415 ' HB1' ' HB3' ' A' ' 84' ' ' LYS . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.814 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.817 ' HG2' HG12 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.814 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.774 HG13 ' HB ' ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.903 HD13 HG21 ' A' ' 59' ' ' VAL . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.871 ' CE ' HD12 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.459 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.876 HG21 ' HG3' ' A' ' 99' ' ' GLU . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.903 HG21 HD13 ' A' ' 51' ' ' LEU . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.602 ' HD2' HD23 ' A' ' 38' ' ' LEU . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.633 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.551 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.631 ' HZ ' HD13 ' A' ' 38' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.77 ' HA ' HG23 ' A' ' 75' ' ' VAL . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.77 HG23 ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.602 HD23 ' ND2' ' A' ' 83' ' ' ASN . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.602 ' ND2' HD23 ' A' ' 78' ' ' LEU . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.415 ' HB3' ' HB1' ' A' ' 41' ' ' ALA . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.648 ' O ' HG22 ' A' ' 88' ' ' THR . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.488 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.539 HD23 ' C ' ' A' ' 87' ' ' LEU . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.718 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.786 HG21 ' HB3' ' A' ' 154' ' ' MET . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.718 HD22 ' O ' ' A' ' 88' ' ' THR . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.464 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.549 ' CD1' HG21 ' A' ' 113' ' ' THR . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.665 ' CD2' HG13 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.815 ' O ' HG23 ' A' ' 114' ' ' VAL . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.839 HG22 ' HA ' ' A' ' 113' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.876 ' HG3' HG21 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 100' ' ' VAL . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.686 ' HB3' HD11 ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASP . . . . . 0.443 ' OD2' HG23 ' A' ' 100' ' ' VAL . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 106' ' ' THR . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' THR . . . . . 0.449 HG22 HD12 ' A' ' 105' ' ' LEU . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.443 ' HG3' HD12 ' A' ' 123' ' ' LEU . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.405 ' HG2' ' CB ' ' A' ' 102' ' ' SER . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 119' ' ' LEU . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.839 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.815 HG23 ' O ' ' A' ' 95' ' ' VAL . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.417 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 110' ' ' THR . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.589 HG12 ' HB2' ' A' ' 102' ' ' SER . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.686 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.805 0.252 . . . . 0.0 112.24 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.515 HG23 HG13 ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 0.492 HD13 ' HB3' ' A' ' 147' ' ' HIS . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.418 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.804 ' O ' HG13 ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.923 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.515 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.453 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.804 HG13 ' O ' ' A' ' 139' ' ' VAL . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ILE . . . . . 0.923 HG23 ' HB2' ' A' ' 141' ' ' ALA . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HD13 ' A' ' 134' ' ' ILE . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 63' ' ' THR . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 1.064 HG21 HD13 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 1.064 HD13 HG21 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 154' ' ' MET . . . . . 0.786 ' HB3' HG21 ' A' ' 90' ' ' ILE . 2.4 mtm . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.732 ' CG ' ' HB1' ' A' ' 141' ' ' ALA . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.761 HD12 ' HZ2' ' A' ' 52' ' ' LYS . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.416 ' HG3' ' O ' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.935 HG22 ' HB2' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . 0.935 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.826 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.533 ' O ' ' CG2' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.858 HD22 ' HG2' ' A' ' 62' ' ' PRO . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.826 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.572 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.656 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.805 ' HG2' HG22 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 1.042 HD11 HD22 ' A' ' 91' ' ' LEU . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.805 HG22 ' HG2' ' A' ' 43' ' ' GLU . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.732 ' CD1' HD23 ' A' ' 47' ' ' LEU . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' LYS . . . . . 0.761 ' HZ2' HD12 ' A' ' 25' ' ' ILE . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.452 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.607 HG13 ' CD2' ' A' ' 94' ' ' HIS . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ALA . . . . . 0.792 ' HB1' HD11 ' A' ' 38' ' ' LEU . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.858 ' HG2' HD22 ' A' ' 38' ' ' LEU . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.42 ' N ' HG13 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 62' ' ' PRO . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PHE . . . . . 0.677 ' CD2' HD23 ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.976 HD11 HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 HD13 ' A' ' 70' ' ' LEU . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.689 HG22 HD12 ' A' ' 79' ' ' LEU . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LEU . . . . . 0.976 HD22 HD11 ' A' ' 70' ' ' LEU . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LEU . . . . . 0.689 HD12 HG22 ' A' ' 75' ' ' VAL . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.461 ' HA ' ' HE3' ' A' ' 84' ' ' LYS . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LYS . . . . . 0.461 ' HE3' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LYS . . . . . 0.435 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.695 ' O ' HD23 ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 90' ' ' ILE . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 89' ' ' GLU . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 1.042 HD22 HD11 ' A' ' 47' ' ' LEU . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.526 ' N ' HD12 ' A' ' 91' ' ' LEU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' TYR . . . . . 0.711 ' O ' HG21 ' A' ' 113' ' ' THR . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' HIS . . . . . 0.607 ' CD2' HG13 ' A' ' 59' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.804 ' O ' HG23 ' A' ' 114' ' ' VAL . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.777 HG22 ' HA ' ' A' ' 113' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 100' ' ' VAL . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.473 ' CB ' HG12 ' A' ' 121' ' ' VAL . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' SER . . . . . 0.497 ' HB3' HD13 ' A' ' 123' ' ' LEU . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASP . . . . . 0.453 ' HB3' HD23 ' A' ' 105' ' ' LEU . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.453 HD23 ' HB3' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' MET . . . . . 0.602 ' HE3' HG21 ' A' ' 121' ' ' VAL . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.777 ' HA ' HG22 ' A' ' 96' ' ' VAL . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.804 HG23 ' O ' ' A' ' 95' ' ' VAL . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' N ' ' HB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.628 ' O ' HG23 ' A' ' 113' ' ' THR . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LEU . . . . . 0.61 HD23 ' HB2' ' A' ' 130' ' ' ASN . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' THR . . . . . 0.782 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' VAL . . . . . 0.602 HG21 ' HE3' ' A' ' 109' ' ' MET . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 103' ' ' SER . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.978 0.324 . . . . 0.0 112.395 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 1.014 HG21 HD11 ' A' ' 134' ' ' ILE . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASN . . . . . 0.61 ' HB2' HD23 ' A' ' 119' ' ' LEU . 4.1 t30 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.67 HG21 HD22 ' A' ' 153' ' ' LEU . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' ILE . . . . . 1.014 HD11 HG21 ' A' ' 129' ' ' VAL . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' PRO . . . . . 0.499 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASP . . . . . 0.482 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.8 ' O ' HG12 ' A' ' 145' ' ' VAL . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ALA . . . . . 0.732 ' HB1' ' CG ' ' A' ' 24' ' ' ASP . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLY . . . . . 0.452 ' HA3' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 139' ' ' VAL . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' HIS . . . . . 0.605 ' HB3' HD13 ' A' ' 134' ' ' ILE . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.964 HG21 HD21 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' VAL . . . . . 0.554 HG13 HD21 ' A' ' 70' ' ' LEU . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' LEU . . . . . 0.964 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.855 HG12 HG21 ' A' ' 59' ' ' VAL . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.623 ' HB ' HG13 ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.731 HG21 ' HB2' ' A' ' 35' ' ' PHE . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 31' ' ' GLY . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.731 ' HB2' HG21 ' A' ' 28' ' ' THR . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.52 ' O ' HG21 ' A' ' 40' ' ' THR . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.532 HG21 ' CG ' ' A' ' 67' ' ' PHE . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.658 HD21 HD13 ' A' ' 87' ' ' LEU . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.82 ' HG ' HG23 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.585 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.827 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.637 ' HG3' HG22 ' A' ' 48' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.827 HD12 ' HA ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.637 HG22 ' HG3' ' A' ' 43' ' ' GLU . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.824 HD12 ' HB1' ' A' ' 42' ' ' ALA . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.408 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.645 HG21 ' CD ' ' A' ' 99' ' ' GLU . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.855 HG21 HG12 ' A' ' 25' ' ' ILE . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 61' ' ' ALA . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.736 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.855 ' CE2' HD22 ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.767 HD12 HD12 ' A' ' 78' ' ' LEU . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.855 HD22 ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.549 ' HG2' ' HB1' ' A' ' 41' ' ' ALA . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.651 ' O ' HD13 ' A' ' 90' ' ' ILE . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.658 HD13 HD21 ' A' ' 38' ' ' LEU . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.666 ' O ' HD22 ' A' ' 91' ' ' LEU . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.651 HD13 ' O ' ' A' ' 86' ' ' LYS . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.782 ' O ' HG23 ' A' ' 95' ' ' VAL . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.517 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.464 ' CD2' ' HD3' ' A' ' 155' ' ' PRO . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.485 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 2.4 t-160 -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 91' ' ' LEU . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.719 HG22 ' HA ' ' A' ' 113' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD3' ' CG2' ' A' ' 114' ' ' VAL . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.645 ' CD ' HG21 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.614 HG13 HD21 ' A' ' 105' ' ' LEU . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' MET . . . . . 0.725 ' HE3' HD21 ' A' ' 123' ' ' LEU . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.763 ' HB2' HD11 ' A' ' 123' ' ' LEU . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.546 ' HB3' HD23 ' A' ' 105' ' ' LEU . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.614 HD21 HG13 ' A' ' 100' ' ' VAL . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.516 ' HA ' HD13 ' A' ' 123' ' ' LEU . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.41 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.719 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 95' ' ' VAL . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.517 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.501 HD23 ' HB2' ' A' ' 130' ' ' ASN . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.525 ' O ' HG23 ' A' ' 120' ' ' THR . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.468 ' CG1' ' HE1' ' A' ' 101' ' ' MET . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.763 HD11 ' HB2' ' A' ' 102' ' ' SER . 0.6 OUTLIER -122.18 -65.15 1.14 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -61.29 153.17 27.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.0 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 60.25 24.7 61.5 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.676 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 114.37 101.35 2.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.526 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.36 131.09 23.93 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.433 2.088 . . . . 0.0 112.222 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.842 HG21 HD11 ' A' ' 134' ' ' ILE . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.501 ' HB2' HD23 ' A' ' 119' ' ' LEU . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.842 HD11 HG21 ' A' ' 129' ' ' VAL . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.838 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.547 ' HB2' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.459 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.473 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 139' ' ' VAL . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.547 HG12 ' HB2' ' A' ' 141' ' ' ALA . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HG21 ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.736 HG11 HG23 ' A' ' 63' ' ' THR . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.764 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.631 ' HG ' HG21 ' A' ' 132' ' ' VAL . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.489 ' HE2' HD13 ' A' ' 153' ' ' LEU . 5.3 mmt 59.18 157.67 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.464 ' HD3' ' CD2' ' A' ' 93' ' ' TYR . 60.8 Cg_endo -71.92 148.14 50.99 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.721 2.28 . . . . 0.0 112.402 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 179.974 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.93 ' CG2' HD22 ' A' ' 39' ' ' LEU . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.867 HG21 ' CG ' ' A' ' 52' ' ' LYS . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.406 ' CG ' ' O ' ' A' ' 24' ' ' ASP . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.913 HG22 ' HB2' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.694 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.913 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' CD2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.645 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.93 HD22 ' CG2' ' A' ' 25' ' ' ILE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.694 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.646 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.713 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.619 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 91' ' ' LEU . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.804 ' HA ' HG11 ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.586 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.867 ' CG ' HG21 ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.414 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.545 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.445 ' HB3' HG23 ' A' ' 149' ' ' ILE . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.7 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.418 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.525 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.685 ' CE2' HD22 ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.84 HD21 HG13 ' A' ' 152' ' ' VAL . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.456 HG22 HD13 ' A' ' 70' ' ' LEU . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.477 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.685 HD22 ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.449 ' HA ' ' HG2' ' A' ' 84' ' ' LYS . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.477 ' ND2' ' O ' ' A' ' 77' ' ' ASP . 1.3 m-80 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.669 ' O ' HD12 ' A' ' 90' ' ' ILE . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.681 ' O ' HG22 ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 47' ' ' LEU . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.877 ' O ' HG12 ' A' ' 114' ' ' VAL . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.471 ' HA ' ' CB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.868 HG22 ' HA ' ' A' ' 113' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.448 ' CG1' HD23 ' A' ' 105' ' ' LEU . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' MET . . . . . 0.426 ' HE3' ' H ' ' A' ' 102' ' ' SER . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.665 ' HB3' HD22 ' A' ' 123' ' ' LEU . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.592 HD12 ' N ' ' A' ' 106' ' ' THR . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.592 ' N ' HD12 ' A' ' 105' ' ' LEU . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.409 ' HB2' HG21 ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 96' ' ' VAL . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.868 ' HA ' HG22 ' A' ' 96' ' ' VAL . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.877 HG12 ' O ' ' A' ' 92' ' ' THR . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.457 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.662 ' O ' HG23 ' A' ' 113' ' ' THR . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.523 HD13 ' HB2' ' A' ' 130' ' ' ASN . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.506 HG12 ' OG ' ' A' ' 102' ' ' SER . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.69 ' H ' HD23 ' A' ' 123' ' ' LEU . 2.5 pt? -130.04 -41.91 1.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' N ' ' HG ' ' A' ' 123' ' ' LEU . 12.5 tt0 -95.1 152.83 18.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.925 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 67.21 25.53 73.5 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.549 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 123.76 78.29 0.39 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.45 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -49.74 122.03 8.26 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.586 2.191 . . . . 0.0 112.266 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.523 ' HB2' HD13 ' A' ' 119' ' ' LEU . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.876 HG21 ' HB ' ' A' ' 149' ' ' ILE . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.601 HD12 HG21 ' A' ' 129' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' PRO . . . . . 0.662 ' O ' HG23 ' A' ' 139' ' ' VAL . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.733 ' O ' HG12 ' A' ' 145' ' ' VAL . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.601 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 139' ' ' VAL . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.601 HG23 ' HB2' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.406 ' O ' ' HA ' ' A' ' 60' ' ' PHE . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.7 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.876 ' HB ' HG21 ' A' ' 132' ' ' VAL . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.793 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.84 HG13 HD21 ' A' ' 70' ' ' LEU . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.794 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.582 ' HB3' HG21 ' A' ' 90' ' ' ILE . 11.3 mtm 72.47 148.03 0.12 Allowed Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.485 ' HG2' HG23 ' A' ' 90' ' ' ILE . 10.3 Cg_endo -51.72 -24.62 18.39 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.82 2.347 . . . . 0.0 112.345 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.592 ' HA3' HD13 ' A' ' 90' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.393 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.364 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.984 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.944 HG22 ' HG3' ' A' ' 52' ' ' LYS . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.739 ' O ' HG22 ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.969 HG22 ' HB2' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.739 HG22 ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.969 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.669 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.538 ' O ' HG21 ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.664 HG23 HD12 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.904 HD22 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.904 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.511 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.808 HD23 ' CD1' ' A' ' 51' ' ' LEU . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.794 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.647 ' H ' HG13 ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.808 ' CD1' HD23 ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.984 ' CE ' HD12 ' A' ' 25' ' ' ILE . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.505 ' HB ' HG23 ' A' ' 145' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.714 HG13 ' ND1' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.548 ' HB3' HD11 ' A' ' 149' ' ' ILE . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.503 ' HB1' HD21 ' A' ' 38' ' ' LEU . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.542 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.912 ' CE2' HD22 ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.482 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 152' ' ' VAL . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 68' ' ' ALA . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.912 HD22 ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.501 ' ND2' HD23 ' A' ' 78' ' ' LEU . 10.0 t30 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.604 ' O ' HG22 ' A' ' 88' ' ' THR . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.768 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.494 HG21 ' N ' ' A' ' 156' ' ' GLY . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.768 HD22 ' O ' ' A' ' 88' ' ' THR . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.554 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.595 ' CE1' HD21 ' A' ' 119' ' ' LEU . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.714 ' ND1' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.754 ' O ' HG23 ' A' ' 114' ' ' VAL . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 113' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' MET . . . . . 0.533 ' HE2' HG12 ' A' ' 121' ' ' VAL . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' SER . . . . . 0.518 ' C ' HD21 ' A' ' 123' ' ' LEU . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.464 HD12 ' OG1' ' A' ' 106' ' ' THR . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.464 ' OG1' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.627 ' HA ' HG22 ' A' ' 96' ' ' VAL . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 95' ' ' VAL . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.406 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.533 ' O ' HG23 ' A' ' 113' ' ' THR . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.595 HD21 ' CE1' ' A' ' 93' ' ' TYR . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.533 HG12 ' HE2' ' A' ' 101' ' ' MET . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.735 HD12 ' H ' ' A' ' 124' ' ' GLU . 0.3 OUTLIER -155.98 -39.12 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.735 ' H ' HD12 ' A' ' 123' ' ' LEU . 7.3 tt0 -63.82 126.73 28.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.382 . . . . 0.0 111.202 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.88 33.69 86.26 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.898 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 112.56 107.05 2.85 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.512 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.88 150.09 54.75 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.499 2.133 . . . . 0.0 112.37 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.64 HG21 HD12 ' A' ' 153' ' ' LEU . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.478 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' PRO . . . . . 0.506 ' O ' HG23 ' A' ' 139' ' ' VAL . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.495 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.663 ' O ' HG12 ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.483 ' HB3' ' HB ' ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.752 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.514 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 0.2 OUTLIER 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.54 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.483 ' HB ' ' HB3' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.47 ' HB3' HG21 ' A' ' 134' ' ' ILE . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.542 HG11 HG23 ' A' ' 63' ' ' THR . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.581 HD13 HD13 ' A' ' 153' ' ' LEU . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.581 ' H ' HG22 ' A' ' 149' ' ' ILE . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 70' ' ' LEU . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.64 HD12 HG21 ' A' ' 132' ' ' VAL . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.451 ' CB ' HD12 ' A' ' 90' ' ' ILE . 0.6 OUTLIER 62.21 157.16 0.12 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.406 ' HG2' ' HB ' ' A' ' 90' ' ' ILE . 9.7 Cg_endo -51.68 -24.4 17.6 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.916 2.411 . . . . 0.0 112.519 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.494 ' N ' HG21 ' A' ' 90' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.646 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.416 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.923 ' CG2' HD22 ' A' ' 39' ' ' LEU . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.858 ' HB ' HG23 ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . 1.019 HG22 ' HB2' ' A' ' 32' ' ' ALA . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.821 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 1.019 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.535 ' O ' HG21 ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.419 ' CG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.773 HD21 ' HG ' ' A' ' 87' ' ' LEU . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.923 HD22 ' CG2' ' A' ' 25' ' ' ILE . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.821 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.982 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.858 HG23 ' HB ' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.6 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.982 HD12 ' HB1' ' A' ' 42' ' ' ALA . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.554 ' HA3' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.554 ' CE2' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . 1.047 HG23 HG13 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.539 HG13 ' ND1' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.824 ' HB2' HD11 ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 39' ' ' LEU . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.848 HG23 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.726 ' CE2' HD23 ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.585 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.694 HD12 HD22 ' A' ' 78' ' ' LEU . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.585 HG21 ' HA ' ' A' ' 68' ' ' ALA . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASP . . . . . 0.493 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.726 HD23 ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 77' ' ' ASP . 0.6 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.795 HD13 HD11 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.825 HG22 ' HB3' ' A' ' 155' ' ' PRO . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.687 ' CD2' HG21 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.831 ' OH ' HD12 ' A' ' 119' ' ' LEU . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.606 ' CD2' ' HA ' ' A' ' 91' ' ' LEU . 1.3 p80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.723 ' O ' HG23 ' A' ' 114' ' ' VAL . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 1.047 HG13 HG23 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.449 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.409 HG12 ' HB3' ' A' ' 104' ' ' ASP . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' MET . . . . . 0.458 ' HE3' ' H ' ' A' ' 102' ' ' SER . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.655 ' HB3' HD11 ' A' ' 123' ' ' LEU . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 100' ' ' VAL . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.435 ' CG ' HD13 ' A' ' 123' ' ' LEU . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ALA . . . . . 0.952 ' HB3' HD21 ' A' ' 119' ' ' LEU . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.75 HG21 ' CD2' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 95' ' ' VAL . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 113' ' ' THR . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 111' ' ' ALA . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.952 HD21 ' HB3' ' A' ' 111' ' ' ALA . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.655 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER -141.59 -170.18 3.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 63.05 124.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.988 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 66.16 30.17 76.34 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 107.59 92.86 2.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.04 133.69 29.68 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.485 2.124 . . . . 0.0 112.337 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.755 HG21 HD11 ' A' ' 134' ' ' ILE . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.519 ' O ' HG23 ' A' ' 132' ' ' VAL . 1.9 t-20 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.53 HG11 HG22 ' A' ' 149' ' ' ILE . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' SER . . . . . 0.425 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.755 HD11 HG21 ' A' ' 129' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.816 ' O ' HG13 ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.568 ' HB2' ' HB ' ' A' ' 146' ' ' ILE . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.406 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.416 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 6.5 t-20 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.411 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 139' ' ' VAL . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.702 HD13 ' N ' ' A' ' 147' ' ' HIS . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.702 ' N ' HD13 ' A' ' 146' ' ' ILE . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.848 HG11 HG23 ' A' ' 63' ' ' THR . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.683 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLY . . . . . 0.683 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.58 HG23 HD21 ' A' ' 70' ' ' LEU . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.824 HD11 ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.461 ' HG3' ' CZ ' ' A' ' 93' ' ' TYR . 13.5 ptm -141.55 158.02 64.16 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.825 ' HB3' HG22 ' A' ' 90' ' ' ILE . 44.2 Cg_endo -90.39 -17.32 1.5 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 123.017 2.478 . . . . 0.0 112.452 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLY . . . . . 0.438 ' HA2' ' CE2' ' A' ' 93' ' ' TYR . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.508 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.871 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.817 HG12 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.835 HG21 ' HB2' ' A' ' 35' ' ' PHE . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.799 ' HA ' HG23 ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.835 ' HB2' HG21 ' A' ' 28' ' ' THR . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.492 HG21 ' CG ' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.631 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.8 HD22 ' CG2' ' A' ' 25' ' ' ILE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.415 ' HB1' ' HB3' ' A' ' 84' ' ' LYS . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.814 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.817 ' HG2' HG12 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.814 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.774 HG13 ' HB ' ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.903 HD13 HG21 ' A' ' 59' ' ' VAL . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.871 ' CE ' HD12 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.459 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.876 HG21 ' HG3' ' A' ' 99' ' ' GLU . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.903 HG21 HD13 ' A' ' 51' ' ' LEU . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.602 ' HD2' HD23 ' A' ' 38' ' ' LEU . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.633 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.551 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.631 ' HZ ' HD13 ' A' ' 38' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.77 ' HA ' HG23 ' A' ' 75' ' ' VAL . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.77 HG23 ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.602 HD23 ' ND2' ' A' ' 83' ' ' ASN . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.602 ' ND2' HD23 ' A' ' 78' ' ' LEU . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.415 ' HB3' ' HB1' ' A' ' 41' ' ' ALA . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.648 ' O ' HG22 ' A' ' 88' ' ' THR . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.488 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.539 HD23 ' C ' ' A' ' 87' ' ' LEU . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.718 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.786 HG21 ' HB3' ' A' ' 154' ' ' MET . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.718 HD22 ' O ' ' A' ' 88' ' ' THR . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.464 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.549 ' CD1' HG21 ' A' ' 113' ' ' THR . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.665 ' CD2' HG13 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.815 ' O ' HG23 ' A' ' 114' ' ' VAL . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.839 HG22 ' HA ' ' A' ' 113' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.876 ' HG3' HG21 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 100' ' ' VAL . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.686 ' HB3' HD11 ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.443 ' OD2' HG23 ' A' ' 100' ' ' VAL . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 106' ' ' THR . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' THR . . . . . 0.449 HG22 HD12 ' A' ' 105' ' ' LEU . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.443 ' HG3' HD12 ' A' ' 123' ' ' LEU . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.405 ' HG2' ' CB ' ' A' ' 102' ' ' SER . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 119' ' ' LEU . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.839 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.815 HG23 ' O ' ' A' ' 95' ' ' VAL . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.417 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 110' ' ' THR . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.589 HG12 ' HB2' ' A' ' 102' ' ' SER . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.686 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER -135.13 -165.24 1.64 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 67.57 124.93 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.086 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.48 26.88 67.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.621 179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 115.53 103.11 2.4 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.454 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.41 138.23 45.61 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.312 2.008 . . . . 0.0 112.24 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.515 HG23 HG13 ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 0.492 HD13 ' HB3' ' A' ' 147' ' ' HIS . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.418 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.804 ' O ' HG13 ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.923 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.515 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.453 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.804 HG13 ' O ' ' A' ' 139' ' ' VAL . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ILE . . . . . 0.923 HG23 ' HB2' ' A' ' 141' ' ' ALA . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HD13 ' A' ' 134' ' ' ILE . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 63' ' ' THR . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 1.064 HG21 HD13 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 1.064 HD13 HG21 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 154' ' ' MET . . . . . 0.786 ' HB3' HG21 ' A' ' 90' ' ' ILE . 2.4 mtm 62.33 148.37 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.629 ' HG2' HD12 ' A' ' 90' ' ' ILE . 11.2 Cg_endo -52.86 157.1 8.35 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.951 2.434 . . . . 0.0 112.338 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.732 ' CG ' ' HB1' ' A' ' 141' ' ' ALA . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.761 HD12 ' HZ2' ' A' ' 52' ' ' LYS . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.416 ' HG3' ' O ' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.935 HG22 ' HB2' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.935 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.826 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.533 ' O ' ' CG2' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.858 HD22 ' HG2' ' A' ' 62' ' ' PRO . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.826 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.572 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.656 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.805 ' HG2' HG22 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 1.042 HD11 HD22 ' A' ' 91' ' ' LEU . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.805 HG22 ' HG2' ' A' ' 43' ' ' GLU . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.732 ' CD1' HD23 ' A' ' 47' ' ' LEU . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.761 ' HZ2' HD12 ' A' ' 25' ' ' ILE . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.607 HG13 ' CD2' ' A' ' 94' ' ' HIS . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.792 ' HB1' HD11 ' A' ' 38' ' ' LEU . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.858 ' HG2' HD22 ' A' ' 38' ' ' LEU . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.42 ' N ' HG13 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 62' ' ' PRO . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PHE . . . . . 0.677 ' CD2' HD23 ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.976 HD11 HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 HD13 ' A' ' 70' ' ' LEU . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.689 HG22 HD12 ' A' ' 79' ' ' LEU . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.976 HD22 HD11 ' A' ' 70' ' ' LEU . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LEU . . . . . 0.689 HD12 HG22 ' A' ' 75' ' ' VAL . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.461 ' HA ' ' HE3' ' A' ' 84' ' ' LYS . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LYS . . . . . 0.461 ' HE3' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LYS . . . . . 0.435 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.695 ' O ' HD23 ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 90' ' ' ILE . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 89' ' ' GLU . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 1.042 HD22 HD11 ' A' ' 47' ' ' LEU . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.526 ' N ' HD12 ' A' ' 91' ' ' LEU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' TYR . . . . . 0.711 ' O ' HG21 ' A' ' 113' ' ' THR . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' HIS . . . . . 0.607 ' CD2' HG13 ' A' ' 59' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.804 ' O ' HG23 ' A' ' 114' ' ' VAL . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.777 HG22 ' HA ' ' A' ' 113' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 100' ' ' VAL . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.473 ' CB ' HG12 ' A' ' 121' ' ' VAL . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' SER . . . . . 0.497 ' HB3' HD13 ' A' ' 123' ' ' LEU . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.453 ' HB3' HD23 ' A' ' 105' ' ' LEU . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.453 HD23 ' HB3' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' MET . . . . . 0.602 ' HE3' HG21 ' A' ' 121' ' ' VAL . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.777 ' HA ' HG22 ' A' ' 96' ' ' VAL . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.804 HG23 ' O ' ' A' ' 95' ' ' VAL . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' N ' ' HB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.628 ' O ' HG23 ' A' ' 113' ' ' THR . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LEU . . . . . 0.61 HD23 ' HB2' ' A' ' 130' ' ' ASN . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' THR . . . . . 0.782 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' VAL . . . . . 0.602 HG21 ' HE3' ' A' ' 109' ' ' MET . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 103' ' ' SER . 0.1 OUTLIER -132.93 -54.62 0.93 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.01 132.72 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.067 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 87.29 -50.25 4.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.482 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -154.44 81.56 0.17 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.064 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -61.95 112.23 1.45 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.601 2.201 . . . . 0.0 112.395 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 1.014 HG21 HD11 ' A' ' 134' ' ' ILE . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASN . . . . . 0.61 ' HB2' HD23 ' A' ' 119' ' ' LEU . 4.1 t30 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.67 HG21 HD22 ' A' ' 153' ' ' LEU . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ILE . . . . . 1.014 HD11 HG21 ' A' ' 129' ' ' VAL . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' PRO . . . . . 0.499 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . 0.482 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.8 ' O ' HG12 ' A' ' 145' ' ' VAL . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ALA . . . . . 0.732 ' HB1' ' CG ' ' A' ' 24' ' ' ASP . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLY . . . . . 0.452 ' HA3' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 139' ' ' VAL . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' HIS . . . . . 0.605 ' HB3' HD13 ' A' ' 134' ' ' ILE . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.964 HG21 HD21 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' VAL . . . . . 0.554 HG13 HD21 ' A' ' 70' ' ' LEU . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' LEU . . . . . 0.964 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER 66.68 145.2 0.1 OUTLIER Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' PRO . . . . . 0.555 ' HG2' HG23 ' A' ' 90' ' ' ILE . 5.0 Cg_endo -48.32 149.62 6.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.822 2.348 . . . . 0.0 112.333 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.23 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.541 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.855 HG12 HG21 ' A' ' 59' ' ' VAL . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.623 ' HB ' HG13 ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.731 HG21 ' HB2' ' A' ' 35' ' ' PHE . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 31' ' ' GLY . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.731 ' HB2' HG21 ' A' ' 28' ' ' THR . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.52 ' O ' HG21 ' A' ' 40' ' ' THR . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.532 HG21 ' CG ' ' A' ' 67' ' ' PHE . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.658 HD21 HD13 ' A' ' 87' ' ' LEU . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.82 ' HG ' HG23 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.585 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.827 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.637 ' HG3' HG22 ' A' ' 48' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.827 HD12 ' HA ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.637 HG22 ' HG3' ' A' ' 43' ' ' GLU . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.824 HD12 ' HB1' ' A' ' 42' ' ' ALA . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.408 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.645 HG21 ' CD ' ' A' ' 99' ' ' GLU . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.855 HG21 HG12 ' A' ' 25' ' ' ILE . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 61' ' ' ALA . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.736 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.855 ' CE2' HD22 ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.767 HD12 HD12 ' A' ' 78' ' ' LEU . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.855 HD22 ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.549 ' HG2' ' HB1' ' A' ' 41' ' ' ALA . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.651 ' O ' HD13 ' A' ' 90' ' ' ILE . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.658 HD13 HD21 ' A' ' 38' ' ' LEU . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.666 ' O ' HD22 ' A' ' 91' ' ' LEU . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.651 HD13 ' O ' ' A' ' 86' ' ' LYS . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.782 ' O ' HG23 ' A' ' 95' ' ' VAL . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.517 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.409 ' N ' ' HB2' ' A' ' 115' ' ' GLU . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.485 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 0.4 OUTLIER -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 91' ' ' LEU . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.719 HG22 ' HA ' ' A' ' 113' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD3' ' CG2' ' A' ' 114' ' ' VAL . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.645 ' CD ' HG21 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.614 HG13 HD21 ' A' ' 105' ' ' LEU . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . 0.725 ' HE3' HD21 ' A' ' 123' ' ' LEU . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.763 ' HB2' HD11 ' A' ' 123' ' ' LEU . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . 0.546 ' HB3' HD23 ' A' ' 105' ' ' LEU . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.614 HD21 HG13 ' A' ' 100' ' ' VAL . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.516 ' HA ' HD13 ' A' ' 123' ' ' LEU . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.41 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.719 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 95' ' ' VAL . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.517 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.501 HD23 ' HB2' ' A' ' 130' ' ' ASN . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.525 ' O ' HG23 ' A' ' 120' ' ' THR . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.468 ' CG1' ' HE1' ' A' ' 101' ' ' MET . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.763 HD11 ' HB2' ' A' ' 102' ' ' SER . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo . . . . . 0 C--O 1.231 0.146 0 CA-C-O 120.842 0.267 . . . . 0.0 112.222 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.842 HG21 HD11 ' A' ' 134' ' ' ILE . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . 0.501 ' HB2' HD23 ' A' ' 119' ' ' LEU . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 0.842 HD11 HG21 ' A' ' 129' ' ' VAL . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.838 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.547 ' HB2' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.459 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.473 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 139' ' ' VAL . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.547 HG12 ' HB2' ' A' ' 141' ' ' ALA . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HG21 ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.736 HG11 HG23 ' A' ' 63' ' ' THR . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.764 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.631 ' HG ' HG21 ' A' ' 132' ' ' VAL . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . 0.489 ' HE2' HD13 ' A' ' 153' ' ' LEU . 5.3 mmt . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.93 ' CG2' HD22 ' A' ' 39' ' ' LEU . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.867 HG21 ' CG ' ' A' ' 52' ' ' LYS . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.406 ' CG ' ' O ' ' A' ' 24' ' ' ASP . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.913 HG22 ' HB2' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.694 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.913 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' CD2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.645 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.93 HD22 ' CG2' ' A' ' 25' ' ' ILE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.694 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.646 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.713 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.619 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 91' ' ' LEU . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.804 ' HA ' HG11 ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.586 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.867 ' CG ' HG21 ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.414 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.545 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.445 ' HB3' HG23 ' A' ' 149' ' ' ILE . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.7 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.418 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.525 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.685 ' CE2' HD22 ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.84 HD21 HG13 ' A' ' 152' ' ' VAL . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.456 HG22 HD13 ' A' ' 70' ' ' LEU . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.685 HD22 ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.449 ' HA ' ' HG2' ' A' ' 84' ' ' LYS . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.666 HD22 HD23 ' A' ' 78' ' ' LEU . 1.9 m120 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.669 ' O ' HD12 ' A' ' 90' ' ' ILE . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.681 ' O ' HG22 ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 47' ' ' LEU . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.877 ' O ' HG12 ' A' ' 114' ' ' VAL . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.471 ' HA ' ' CB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.868 HG22 ' HA ' ' A' ' 113' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.448 ' CG1' HD23 ' A' ' 105' ' ' LEU . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . 0.426 ' HE3' ' H ' ' A' ' 102' ' ' SER . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.665 ' HB3' HD22 ' A' ' 123' ' ' LEU . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.592 HD12 ' N ' ' A' ' 106' ' ' THR . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.592 ' N ' HD12 ' A' ' 105' ' ' LEU . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.409 ' HB2' HG21 ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 96' ' ' VAL . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.868 ' HA ' HG22 ' A' ' 96' ' ' VAL . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.877 HG12 ' O ' ' A' ' 92' ' ' THR . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.457 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.662 ' O ' HG23 ' A' ' 113' ' ' THR . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.523 HD13 ' HB2' ' A' ' 130' ' ' ASN . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.506 HG12 ' OG ' ' A' ' 102' ' ' SER . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.69 ' H ' HD23 ' A' ' 123' ' ' LEU . 2.5 pt? . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo . . . . . 0 C--O 1.232 0.187 0 CA-C-O 120.762 0.234 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . 0.523 ' HB2' HD13 ' A' ' 119' ' ' LEU . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.876 HG21 ' HB ' ' A' ' 149' ' ' ILE . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 0.601 HD12 HG21 ' A' ' 129' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . 0.662 ' O ' HG23 ' A' ' 139' ' ' VAL . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.733 ' O ' HG12 ' A' ' 145' ' ' VAL . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.601 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 139' ' ' VAL . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.601 HG23 ' HB2' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.406 ' O ' ' HA ' ' A' ' 60' ' ' PHE . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.7 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.876 ' HB ' HG21 ' A' ' 132' ' ' VAL . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.793 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.84 HG13 HD21 ' A' ' 70' ' ' LEU . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.794 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . 0.582 ' HB3' HG21 ' A' ' 90' ' ' ILE . 11.3 mtm . . . . . 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.984 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.944 HG22 ' HG3' ' A' ' 52' ' ' LYS . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.739 ' O ' HG22 ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.969 HG22 ' HB2' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.739 HG22 ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.969 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.669 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.538 ' O ' HG21 ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.664 HG23 HD12 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.904 HD22 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.904 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.511 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.808 HD23 ' CD1' ' A' ' 51' ' ' LEU . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.794 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.647 ' H ' HG13 ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.808 ' CD1' HD23 ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.984 ' CE ' HD12 ' A' ' 25' ' ' ILE . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.505 ' HB ' HG23 ' A' ' 145' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.914 HG13 ' CD2' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.548 ' HB3' HD11 ' A' ' 149' ' ' ILE . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.503 ' HB1' HD21 ' A' ' 38' ' ' LEU . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.542 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.912 ' CE2' HD22 ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.482 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 152' ' ' VAL . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 68' ' ' ALA . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.912 HD22 ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.547 ' ND2' HD23 ' A' ' 78' ' ' LEU . 5.9 t-20 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.604 ' O ' HG22 ' A' ' 88' ' ' THR . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.768 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.451 HD12 ' CB ' ' A' ' 154' ' ' MET . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.768 HD22 ' O ' ' A' ' 88' ' ' THR . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.554 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.595 ' CE1' HD21 ' A' ' 119' ' ' LEU . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.914 ' CD2' HG13 ' A' ' 59' ' ' VAL . 1.0 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.754 ' O ' HG23 ' A' ' 114' ' ' VAL . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 113' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . 0.533 ' HE2' HG12 ' A' ' 121' ' ' VAL . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . 0.518 ' C ' HD21 ' A' ' 123' ' ' LEU . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.464 HD12 ' OG1' ' A' ' 106' ' ' THR . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.464 ' OG1' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.627 ' HA ' HG22 ' A' ' 96' ' ' VAL . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 95' ' ' VAL . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.406 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.533 ' O ' HG23 ' A' ' 113' ' ' THR . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.595 HD21 ' CE1' ' A' ' 93' ' ' TYR . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.533 HG12 ' HE2' ' A' ' 101' ' ' MET . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.518 HD21 ' C ' ' A' ' 103' ' ' SER . 0.3 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo . . . . . 0 C--O 1.232 0.221 0 CA-C-O 120.814 0.256 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.64 HG21 HD12 ' A' ' 153' ' ' LEU . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.478 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . 0.506 ' O ' HG23 ' A' ' 139' ' ' VAL . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.495 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.663 ' O ' HG12 ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.483 ' HB3' ' HB ' ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.752 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.514 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 5.6 t-20 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.54 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.483 ' HB ' ' HB3' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.47 ' HB3' HG21 ' A' ' 134' ' ' ILE . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.542 HG11 HG23 ' A' ' 63' ' ' THR . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.581 HD13 HD13 ' A' ' 153' ' ' LEU . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.581 ' H ' HG22 ' A' ' 149' ' ' ILE . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 70' ' ' LEU . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.64 HD12 HG21 ' A' ' 132' ' ' VAL . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . 0.451 ' CB ' HD12 ' A' ' 90' ' ' ILE . 0.6 OUTLIER . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.416 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.923 ' CG2' HD22 ' A' ' 39' ' ' LEU . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.858 ' HB ' HG23 ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 1.019 HG22 ' HB2' ' A' ' 32' ' ' ALA . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.821 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 1.019 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.535 ' O ' HG21 ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.419 ' CG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.773 HD21 ' HG ' ' A' ' 87' ' ' LEU . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.923 HD22 ' CG2' ' A' ' 25' ' ' ILE . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.821 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.982 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.858 HG23 ' HB ' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.6 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.982 HD12 ' HB1' ' A' ' 42' ' ' ALA . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.41 ' CD ' ' ND2' ' A' ' 143' ' ' ASN . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.554 ' HA3' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.554 ' CE2' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 1.047 HG23 HG13 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.739 HG13 ' CD2' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.824 ' HB2' HD11 ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 39' ' ' LEU . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.848 HG23 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.726 ' CE2' HD23 ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.585 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.694 HD12 HD22 ' A' ' 78' ' ' LEU . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.585 HG21 ' HA ' ' A' ' 68' ' ' ALA . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.726 HD23 ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.56 HD21 HD12 ' A' ' 78' ' ' LEU . 0.9 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.795 HD13 HD11 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.795 HD11 HD13 ' A' ' 87' ' ' LEU . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.687 ' CD2' HG21 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.831 ' OH ' HD12 ' A' ' 119' ' ' LEU . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.739 ' CD2' HG13 ' A' ' 59' ' ' VAL . 1.5 p-80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.723 ' O ' HG23 ' A' ' 114' ' ' VAL . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 1.047 HG13 HG23 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.449 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.409 HG12 ' HB3' ' A' ' 104' ' ' ASP . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . 0.458 ' HE3' ' H ' ' A' ' 102' ' ' SER . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.655 ' HB3' HD11 ' A' ' 123' ' ' LEU . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 100' ' ' VAL . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.435 ' CG ' HD13 ' A' ' 123' ' ' LEU . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . 0.952 ' HB3' HD21 ' A' ' 119' ' ' LEU . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.75 HG21 ' CD2' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 95' ' ' VAL . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 113' ' ' THR . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 111' ' ' ALA . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.952 HD21 ' HB3' ' A' ' 111' ' ' ALA . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.655 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo . . . . . 0 C--O 1.232 0.189 0 CA-C-O 120.922 0.301 . . . . 0.0 112.337 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.755 HG21 HD11 ' A' ' 134' ' ' ILE . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . 0.519 ' O ' HG23 ' A' ' 132' ' ' VAL . 4.4 t30 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.53 HG11 HG22 ' A' ' 149' ' ' ILE . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . 0.425 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 0.755 HD11 HG21 ' A' ' 129' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.462 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.816 ' O ' HG13 ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.568 ' HB2' ' HB ' ' A' ' 146' ' ' ILE . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.406 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.416 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 53.6 t30 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.411 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 139' ' ' VAL . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.702 HD13 ' N ' ' A' ' 147' ' ' HIS . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.702 ' N ' HD13 ' A' ' 146' ' ' ILE . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.848 HG11 HG23 ' A' ' 63' ' ' THR . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.683 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . 0.683 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.58 HG23 HD21 ' A' ' 70' ' ' LEU . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.824 HD11 ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . 0.461 ' HG3' ' CZ ' ' A' ' 93' ' ' TYR . 13.5 ptm . . . . . 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.871 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.817 HG12 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.835 HG21 ' HB2' ' A' ' 35' ' ' PHE . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.799 ' HA ' HG23 ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.835 ' HB2' HG21 ' A' ' 28' ' ' THR . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . 0.492 HG21 ' CG ' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.631 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.8 HD22 ' CG2' ' A' ' 25' ' ' ILE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.415 ' HB1' ' HB3' ' A' ' 84' ' ' LYS . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.814 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.817 ' HG2' HG12 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.814 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.774 HG13 ' HB ' ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.903 HD13 HG21 ' A' ' 59' ' ' VAL . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.871 ' CE ' HD12 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.459 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.876 HG21 ' HG3' ' A' ' 99' ' ' GLU . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.903 HG21 HD13 ' A' ' 51' ' ' LEU . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.602 ' HD2' HD23 ' A' ' 38' ' ' LEU . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.633 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.551 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.631 ' HZ ' HD13 ' A' ' 38' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.77 ' HA ' HG23 ' A' ' 75' ' ' VAL . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.77 HG23 ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.602 HD23 ' ND2' ' A' ' 83' ' ' ASN . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.602 ' ND2' HD23 ' A' ' 78' ' ' LEU . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.415 ' HB3' ' HB1' ' A' ' 41' ' ' ALA . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.648 ' O ' HG22 ' A' ' 88' ' ' THR . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.488 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.539 HD23 ' C ' ' A' ' 87' ' ' LEU . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.718 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.786 HG21 ' HB3' ' A' ' 154' ' ' MET . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.718 HD22 ' O ' ' A' ' 88' ' ' THR . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.464 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.549 ' CD1' HG21 ' A' ' 113' ' ' THR . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.665 ' CD2' HG13 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.815 ' O ' HG23 ' A' ' 114' ' ' VAL . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.839 HG22 ' HA ' ' A' ' 113' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.876 ' HG3' HG21 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 100' ' ' VAL . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.686 ' HB3' HD11 ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . 0.443 ' OD2' HG23 ' A' ' 100' ' ' VAL . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 106' ' ' THR . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . 0.449 HG22 HD12 ' A' ' 105' ' ' LEU . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.443 ' HG3' HD12 ' A' ' 123' ' ' LEU . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.405 ' HG2' ' CB ' ' A' ' 102' ' ' SER . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 119' ' ' LEU . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.839 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.815 HG23 ' O ' ' A' ' 95' ' ' VAL . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.417 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 110' ' ' THR . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.589 HG12 ' HB2' ' A' ' 102' ' ' SER . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.686 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo . . . . . 0 C--O 1.231 0.147 0 CA-C-O 120.805 0.252 . . . . 0.0 112.24 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.515 HG23 HG13 ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 0.492 HD13 ' HB3' ' A' ' 147' ' ' HIS . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.418 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.804 ' O ' HG13 ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.923 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.515 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.453 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.804 HG13 ' O ' ' A' ' 139' ' ' VAL . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . 0.923 HG23 ' HB2' ' A' ' 141' ' ' ALA . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HD13 ' A' ' 134' ' ' ILE . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 63' ' ' THR . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 1.064 HG21 HD13 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 1.064 HD13 HG21 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . 0.786 ' HB3' HG21 ' A' ' 90' ' ' ILE . 2.4 mtm . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.732 ' CG ' ' HB1' ' A' ' 141' ' ' ALA . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.761 HD12 ' HZ2' ' A' ' 52' ' ' LYS . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.416 ' HG3' ' O ' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.935 HG22 ' HB2' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . 0.935 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.826 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.533 ' O ' ' CG2' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.858 HD22 ' HG2' ' A' ' 62' ' ' PRO . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.826 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.572 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.656 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.805 ' HG2' HG22 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 1.042 HD11 HD22 ' A' ' 91' ' ' LEU . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.805 HG22 ' HG2' ' A' ' 43' ' ' GLU . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.732 ' CD1' HD23 ' A' ' 47' ' ' LEU . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' LYS . . . . . 0.761 ' HZ2' HD12 ' A' ' 25' ' ' ILE . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.452 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.607 HG13 ' CD2' ' A' ' 94' ' ' HIS . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ALA . . . . . 0.792 ' HB1' HD11 ' A' ' 38' ' ' LEU . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.858 ' HG2' HD22 ' A' ' 38' ' ' LEU . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.42 ' N ' HG13 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 62' ' ' PRO . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PHE . . . . . 0.677 ' CD2' HD23 ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.976 HD11 HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 HD13 ' A' ' 70' ' ' LEU . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.689 HG22 HD12 ' A' ' 79' ' ' LEU . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LEU . . . . . 0.976 HD22 HD11 ' A' ' 70' ' ' LEU . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LEU . . . . . 0.689 HD12 HG22 ' A' ' 75' ' ' VAL . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.461 ' HA ' ' HE3' ' A' ' 84' ' ' LYS . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LYS . . . . . 0.461 ' HE3' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . 0.435 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.695 ' O ' HD23 ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 90' ' ' ILE . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 89' ' ' GLU . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 1.042 HD22 HD11 ' A' ' 47' ' ' LEU . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.526 ' N ' HD12 ' A' ' 91' ' ' LEU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . 0.711 ' O ' HG21 ' A' ' 113' ' ' THR . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' HIS . . . . . 0.607 ' CD2' HG13 ' A' ' 59' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.804 ' O ' HG23 ' A' ' 114' ' ' VAL . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.777 HG22 ' HA ' ' A' ' 113' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 100' ' ' VAL . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.473 ' CB ' HG12 ' A' ' 121' ' ' VAL . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . 0.497 ' HB3' HD13 ' A' ' 123' ' ' LEU . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . 0.453 ' HB3' HD23 ' A' ' 105' ' ' LEU . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.453 HD23 ' HB3' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' MET . . . . . 0.602 ' HE3' HG21 ' A' ' 121' ' ' VAL . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.777 ' HA ' HG22 ' A' ' 96' ' ' VAL . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.804 HG23 ' O ' ' A' ' 95' ' ' VAL . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . 0.464 ' N ' ' HB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.628 ' O ' HG23 ' A' ' 113' ' ' THR . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LEU . . . . . 0.61 HD23 ' HB2' ' A' ' 130' ' ' ASN . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' THR . . . . . 0.782 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' VAL . . . . . 0.602 HG21 ' HE3' ' A' ' 109' ' ' MET . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 103' ' ' SER . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.978 0.324 . . . . 0.0 112.395 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 1.014 HG21 HD11 ' A' ' 134' ' ' ILE . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASN . . . . . 0.61 ' HB2' HD23 ' A' ' 119' ' ' LEU . 14.3 t-20 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.67 HG21 HD22 ' A' ' 153' ' ' LEU . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' ILE . . . . . 1.014 HD11 HG21 ' A' ' 129' ' ' VAL . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' PRO . . . . . 0.499 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . 0.482 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.8 ' O ' HG12 ' A' ' 145' ' ' VAL . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ALA . . . . . 0.732 ' HB1' ' CG ' ' A' ' 24' ' ' ASP . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLY . . . . . 0.452 ' HA3' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 139' ' ' VAL . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' HIS . . . . . 0.605 ' HB3' HD13 ' A' ' 134' ' ' ILE . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.964 HG21 HD21 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' VAL . . . . . 0.554 HG13 HD21 ' A' ' 70' ' ' LEU . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' LEU . . . . . 0.964 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.459 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 1.8 t70 . . . . . 0 N--CA 1.457 -0.12 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.855 HG12 HG21 ' A' ' 59' ' ' VAL . 2.7 mp -66.13 -39.73 85.19 Favored 'Isoleucine or valine' 0 C--O 1.242 0.692 0 CA-C-O 122.005 0.907 . . . . 0.0 108.951 178.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.623 ' HB ' HG13 ' A' ' 48' ' ' VAL . 10.4 m -66.02 -31.18 52.54 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-N 114.629 -1.168 . . . . 0.0 109.253 178.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.07 -30.8 71.88 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.794 178.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.731 HG21 ' HB2' ' A' ' 35' ' ' PHE . 88.7 m -62.63 -52.75 62.11 Favored 'General case' 0 N--CA 1.454 -0.225 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -42.64 -44.64 4.34 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-O 121.017 0.436 . . . . 0.0 110.66 177.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.68 -44.2 85.61 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.89 179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.502 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -106.15 -72.65 0.84 Allowed Glycine 0 C--N 1.33 0.228 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.404 179.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.502 ' HB3' ' O ' ' A' ' 31' ' ' GLY . . . 75.17 72.06 0.09 Allowed 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.026 0.441 . . . . 0.0 111.674 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.17 -25.51 7.85 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.837 -0.696 . . . . 0.0 111.823 179.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.3 m -127.25 -10.18 5.84 Favored 'General case' 0 CA--C 1.532 0.259 0 N-CA-C 111.693 0.257 . . . . 0.0 111.693 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.731 ' HB2' HG21 ' A' ' 28' ' ' THR . 4.6 m-85 -136.04 49.81 2.11 Favored 'General case' 0 CA--C 1.52 -0.208 0 CA-C-O 121.026 0.441 . . . . 0.0 111.476 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.52 ' O ' HG21 ' A' ' 40' ' ' THR . 4.8 t -77.06 -18.44 58.06 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.22 179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.532 HG21 ' CG ' ' A' ' 67' ' ' PHE . 14.8 t -87.67 -21.94 24.96 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 113.809 1.04 . . . . 0.0 113.809 -178.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.658 HD21 HD13 ' A' ' 87' ' ' LEU . 3.5 tm? -142.55 -45.16 0.32 Allowed 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.82 ' HG ' HG23 ' A' ' 25' ' ' ILE . 0.2 OUTLIER -74.55 -39.94 62.01 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.864 0.364 . . . . 0.0 111.156 -178.172 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 14.9 t -52.34 -34.4 47.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.516 0.674 . . . . 0.0 110.044 179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.585 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -75.73 -13.95 60.32 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.509 -0.768 . . . . 0.0 111.447 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.827 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -55.22 -57.11 13.13 Favored 'General case' 0 C--O 1.225 -0.2 0 C-N-CA 120.713 -0.395 . . . . 0.0 111.054 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.637 ' HG3' HG22 ' A' ' 48' ' ' VAL . 0.1 OUTLIER -78.28 -30.34 48.41 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.386 0.613 . . . . 0.0 109.608 178.96 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.585 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -77.96 -2.86 39.0 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.873 -179.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.71 13.65 26.32 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.847 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 78.6 27.31 57.39 Favored Glycine 0 N--CA 1.444 -0.817 0 C-N-CA 120.345 -0.931 . . . . 0.0 111.211 -178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.827 HD12 ' HA ' ' A' ' 42' ' ' ALA . 5.9 mt -108.08 -3.39 18.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.852 0.358 . . . . 0.0 110.598 179.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.637 HG22 ' HG3' ' A' ' 43' ' ' GLU . 2.1 t -43.65 -61.37 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.889 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -69.1 -17.96 63.92 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.61 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.1 m -85.06 -52.37 6.0 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.824 HD12 ' HB1' ' A' ' 42' ' ' ALA . 26.8 mt -73.12 -52.79 12.92 Favored 'General case' 0 C--N 1.328 -0.359 0 C-N-CA 120.952 -0.299 . . . . 0.0 110.846 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.9 tttt -95.54 37.48 1.19 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.65 -64.39 3.74 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 121.096 -0.573 . . . . 0.0 112.661 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -178.21 77.59 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.424 0 C-N-CA 120.618 -0.433 . . . . 0.0 112.111 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 150.44 156.95 7.54 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.226 -0.988 . . . . 0.0 113.001 179.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.408 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 17.8 Cg_endo -60.54 118.39 5.25 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 121.856 1.704 . . . . 0.0 110.992 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 4.0 m-85 -119.65 125.1 47.91 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.444 0.64 . . . . 0.0 111.507 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.645 HG21 ' CD ' ' A' ' 99' ' ' GLU . 1.5 t -91.82 122.12 34.06 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.944 -1.025 . . . . 0.0 111.382 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.855 HG21 HG12 ' A' ' 25' ' ' ILE . 7.8 m -132.26 117.09 31.07 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.372 0 N-CA-C 110.313 -0.254 . . . . 0.0 110.313 179.195 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.454 ' CD1' ' CE ' ' A' ' 154' ' ' MET . 23.9 m-85 -78.41 88.43 4.41 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -98.2 113.47 64.01 Favored Pre-proline 0 C--N 1.323 -0.562 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.9 -179.036 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 61' ' ' ALA . 32.2 Cg_endo -64.49 164.39 23.64 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.319 2.013 . . . . 0.0 112.708 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.736 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -78.29 153.91 31.37 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.458 179.916 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -54.53 -23.96 18.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.674 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -76.17 -33.51 59.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.488 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -61.39 -43.96 97.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.722 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.855 ' CE2' HD22 ' A' ' 78' ' ' LEU . 1.9 m-85 -61.16 -45.59 93.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.454 179.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.94 -18.84 60.84 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.647 179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -70.28 -41.25 73.66 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.123 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.767 HD12 HD12 ' A' ' 78' ' ' LEU . 81.7 mt -52.6 123.62 31.03 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.929 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -76.75 -167.92 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 122.413 2.075 . . . . 0.0 112.12 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 54.48 -158.63 0.18 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.72 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -92.56 27.02 11.43 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.597 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 53.4 m -74.25 -32.48 62.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 120.895 0.379 . . . . 0.0 109.988 179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.2 p -70.98 -37.28 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -68.08 -38.07 81.96 Favored 'General case' 0 N--CA 1.447 -0.609 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.73 178.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -70.42 -36.79 74.23 Favored 'General case' 0 N--CA 1.453 -0.295 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.213 178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.855 HD22 ' CE2' ' A' ' 67' ' ' PHE . 6.7 mt -77.15 -11.94 59.88 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.674 179.073 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.8 tp -87.02 -20.13 27.66 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.043 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.436 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 25.7 mttt -81.95 144.99 52.4 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.754 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.1 -12.95 37.17 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 122.486 2.124 . . . . 0.0 112.497 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -69.6 -28.72 66.19 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.396 -0.365 . . . . 0.0 111.533 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 6.1 p30 -61.71 -39.46 91.57 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.732 0.301 . . . . 0.0 110.92 -179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.549 ' HG2' ' HB1' ' A' ' 41' ' ' ALA . 15.7 tptp -63.67 -29.2 70.46 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.868 0.366 . . . . 0.0 110.509 179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.71 -37.99 85.82 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.286 179.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.651 ' O ' HD13 ' A' ' 90' ' ' ILE . 0.0 OUTLIER -64.37 -51.14 64.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.113 179.39 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.658 HD13 HD21 ' A' ' 38' ' ' LEU . 1.8 mt -59.47 -30.86 68.83 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.37 179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.666 ' O ' HD22 ' A' ' 91' ' ' LEU . 88.0 m -60.57 -49.35 77.89 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.059 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.511 ' HG3' ' N ' ' A' ' 90' ' ' ILE . 0.9 OUTLIER -56.82 -38.61 72.86 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.76 0.314 . . . . 0.0 110.711 179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.651 HD13 ' O ' ' A' ' 86' ' ' LYS . 0.1 OUTLIER -106.86 26.16 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.811 179.362 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.782 ' O ' HG23 ' A' ' 95' ' ' VAL . 2.0 pt? -55.1 -35.01 64.16 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.088 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.517 ' HB ' ' N ' ' A' ' 115' ' ' GLU . 0.7 OUTLIER -51.81 -44.03 63.33 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.029 -179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.464 ' CD2' ' HD3' ' A' ' 155' ' ' PRO . 14.7 t80 -61.0 -30.75 70.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.114 0.483 . . . . 0.0 110.161 179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.485 ' CG ' ' HG3' ' A' ' 154' ' ' MET . 0.4 OUTLIER -89.11 -23.75 22.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.584 179.525 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.782 HG23 ' O ' ' A' ' 91' ' ' LEU . 26.8 t -96.81 131.89 42.53 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.788 -179.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.719 HG22 ' HA ' ' A' ' 113' ' ' THR . 6.0 t -147.34 114.8 4.18 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.564 179.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.421 ' HD3' ' CG2' ' A' ' 114' ' ' VAL . 79.2 Cg_endo -77.69 135.79 14.73 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.524 2.149 . . . . 0.0 112.713 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.56 73.01 0.53 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.547 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.645 ' CD ' HG21 ' A' ' 58' ' ' THR . 14.9 tt0 -129.02 100.92 5.83 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.836 0.35 . . . . 0.0 110.821 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.614 HG13 HD21 ' A' ' 105' ' ' LEU . 11.9 p -91.21 146.67 5.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.973 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . 0.725 ' HE3' HD21 ' A' ' 123' ' ' LEU . 8.5 tpt -60.93 139.33 58.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.933 -179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.763 ' HB2' HD11 ' A' ' 123' ' ' LEU . 1.6 m -50.49 -44.13 55.79 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.297 -179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 76.8 p -54.19 -26.57 28.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.755 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.546 ' HB3' HD23 ' A' ' 105' ' ' LEU . 3.4 t70 -62.92 -32.03 73.23 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.867 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.614 HD21 HG13 ' A' ' 100' ' ' VAL . 0.0 OUTLIER -117.61 -79.16 0.59 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.852 179.96 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 21.2 p -137.12 154.95 50.16 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.931 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.516 ' HA ' HD13 ' A' ' 123' ' ' LEU . 7.2 mt-10 -88.66 112.97 23.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.046 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 117.35 68.75 0.38 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.749 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 6.4 ptt? -133.13 -167.68 1.96 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.721 0.296 . . . . 0.0 110.832 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 17.9 p -124.45 170.09 11.2 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.316 0.579 . . . . 0.0 111.254 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.41 ' HB2' ' CG2' ' A' ' 121' ' ' VAL . . . -131.01 100.55 5.27 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.009 -179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.424 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 9.6 tt0 -84.71 132.91 34.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.046 -0.525 . . . . 0.0 111.528 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.719 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.7 p -98.91 147.56 24.84 Favored 'General case' 0 C--O 1.233 0.229 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.583 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.733 HG23 ' O ' ' A' ' 95' ' ' VAL . 43.7 t -47.74 -50.03 9.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.147 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.689 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.517 ' N ' ' HB ' ' A' ' 92' ' ' THR . 4.1 tt0 -49.51 -38.86 32.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.552 179.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 124.35 66.43 0.2 Allowed Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.42 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.424 ' O ' ' HA ' ' A' ' 112' ' ' GLU . . . -150.1 115.15 0.7 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.811 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.51 107.94 20.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.879 0.371 . . . . 0.0 111.219 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.501 HD23 ' HB2' ' A' ' 130' ' ' ASN . 11.0 mp -93.33 171.77 8.71 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.486 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.525 ' O ' HG23 ' A' ' 120' ' ' THR . 6.0 t -106.21 114.42 28.53 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.934 0.397 . . . . 0.0 111.136 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.468 ' CG1' ' HE1' ' A' ' 101' ' ' MET . 12.6 t -96.89 106.96 19.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.476 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 10.6 t -114.92 140.49 48.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.243 -179.382 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.763 HD11 ' HB2' ' A' ' 102' ' ' SER . 0.6 OUTLIER -122.18 -65.15 1.14 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.821 179.781 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -61.29 153.17 27.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.0 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 60.25 24.7 61.5 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.676 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 114.37 101.35 2.41 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.526 180.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.36 131.09 23.93 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.433 2.088 . . . . 0.0 112.222 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -163.57 174.08 12.23 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.916 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.842 HG21 HD11 ' A' ' 134' ' ' ILE . 25.2 t -149.93 113.96 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.051 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.501 ' HB2' HD23 ' A' ' 119' ' ' LEU . 56.2 t30 51.89 26.62 3.73 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.378 179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.18 -9.6 57.89 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.599 -0.81 . . . . 0.0 113.415 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 129' ' ' VAL . 18.5 m -111.19 133.61 56.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 117.139 0.469 . . . . 0.0 111.194 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.64 127.93 34.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.842 HD11 HG21 ' A' ' 129' ' ' VAL . 55.5 mt -74.39 72.9 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.347 178.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.2 OUTLIER -27.96 -61.1 0.11 Allowed 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.52 -178.507 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 43.6 tt0 -118.33 85.34 25.08 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 120.737 0.304 . . . . 0.0 111.136 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.31 107.62 2.31 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.793 2.329 . . . . 0.0 112.322 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.527 ' HB3' HG13 ' A' ' 146' ' ' ILE . 50.1 t0 -82.43 -40.87 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.306 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.838 ' O ' HG13 ' A' ' 145' ' ' VAL . 7.4 t 74.34 -60.64 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.485 0.55 . . . . 0.0 112.485 178.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -97.41 114.79 26.67 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.961 0.41 . . . . 0.0 112.077 -178.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.547 ' HB2' HG12 ' A' ' 146' ' ' ILE . . . -91.74 178.16 5.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.816 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -72.84 -21.02 61.01 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.848 0.356 . . . . 0.0 110.7 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.459 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 49.5 t30 -143.21 18.65 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.774 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.473 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 172.59 -118.42 0.71 Allowed Glycine 0 C--N 1.332 0.356 0 C-N-CA 120.413 -0.899 . . . . 0.0 113.158 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 139' ' ' VAL . 94.7 t -133.33 142.86 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 121.048 0.452 . . . . 0.0 111.406 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.547 HG12 ' HB2' ' A' ' 141' ' ' ALA . 3.5 pt -142.38 138.8 29.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.116 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HG21 ' A' ' 134' ' ' ILE . 31.7 m80 -138.2 131.93 31.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.149 179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.736 HG11 HG23 ' A' ' 63' ' ' THR . 95.5 t -93.24 128.37 44.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.292 0 CA-C-O 121.254 0.549 . . . . 0.0 112.175 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.764 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.2 pt -100.48 136.6 31.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.177 177.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -70.82 -9.93 58.52 Favored 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.907 -0.317 . . . . 0.0 110.919 -179.414 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.764 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -132.29 -132.7 3.35 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.457 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 11.7 t -124.13 145.03 31.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.758 0.313 . . . . 0.0 111.348 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.631 ' HG ' HG21 ' A' ' 132' ' ' VAL . 1.5 mt -132.05 174.51 10.11 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.004 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.489 ' HE2' HD13 ' A' ' 153' ' ' LEU . 5.3 mmt 59.18 157.67 0.1 OUTLIER Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.149 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.464 ' HD3' ' CD2' ' A' ' 93' ' ' TYR . 60.8 Cg_endo -71.92 148.14 50.99 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.721 2.28 . . . . 0.0 112.402 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.523 179.974 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.466 ' HA ' ' HB2' ' A' ' 142' ' ' SER . 69.5 m-20 . . . . . 0 N--CA 1.452 -0.357 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.93 ' CG2' HD22 ' A' ' 39' ' ' LEU . 3.3 mp -57.95 -30.92 39.64 Favored 'Isoleucine or valine' 0 C--O 1.25 1.114 0 CA-C-O 122.961 1.362 . . . . 0.0 109.049 177.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.867 HG21 ' CG ' ' A' ' 52' ' ' LYS . 19.7 m -62.25 -26.48 40.37 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 CA-C-N 114.136 -1.393 . . . . 0.0 109.119 178.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.406 ' CG ' ' O ' ' A' ' 24' ' ' ASP . 2.6 pt-20 -60.91 -29.46 69.6 Favored 'General case' 0 N--CA 1.444 -0.774 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 177.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.913 HG22 ' HB2' ' A' ' 32' ' ' ALA . 4.9 m -60.11 -52.67 64.34 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.144 -0.935 . . . . 0.0 108.55 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.694 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -46.42 -36.65 6.74 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.046 -0.524 . . . . 0.0 111.283 178.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -73.14 -33.18 65.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.055 0.455 . . . . 0.0 110.586 179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -167.25 79.04 0.11 Allowed Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.662 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.913 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -80.36 -68.36 0.68 Allowed 'General case' 0 N--CA 1.448 -0.552 0 CA-C-O 120.742 0.306 . . . . 0.0 111.352 -179.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 76.3 -39.23 1.43 Allowed Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.505 -0.855 . . . . 0.0 111.804 -179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 32' ' ' ALA . 40.1 t -110.75 -17.8 13.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.637 0.256 . . . . 0.0 110.604 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CB ' ' HB2' ' A' ' 39' ' ' LEU . 17.0 m-85 -129.48 29.39 5.08 Favored 'General case' 0 CA--C 1.519 -0.239 0 CA-C-O 121.118 0.485 . . . . 0.0 110.596 179.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 40' ' ' THR . 0.7 OUTLIER -64.15 -18.8 64.81 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.914 179.801 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.463 HG21 ' CD2' ' A' ' 67' ' ' PHE . 5.9 t -88.14 -20.64 25.36 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 113.086 0.772 . . . . 0.0 113.086 -179.138 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.645 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 4.0 tp -136.2 -53.95 0.74 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 114.881 1.437 . . . . 0.0 114.881 -177.66 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.93 HD22 ' CG2' ' A' ' 25' ' ' ILE . 13.6 mt -72.06 -38.42 69.47 Favored 'General case' 0 CA--C 1.511 -0.545 0 O-C-N 122.02 -0.425 . . . . 0.0 111.636 -177.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.694 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 6.8 t -52.34 -35.67 51.58 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.523 0.678 . . . . 0.0 110.205 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -78.5 -11.44 59.96 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.885 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.646 ' HA ' HD12 ' A' ' 47' ' ' LEU . . . -56.35 -56.89 15.53 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.943 0.402 . . . . 0.0 110.676 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.713 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.32 -34.24 48.75 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-O 121.589 0.709 . . . . 0.0 109.595 178.466 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.619 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -74.19 -2.84 26.47 Favored 'General case' 0 N--CA 1.441 -0.913 0 CA-C-N 114.649 -1.159 . . . . 0.0 112.0 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -105.58 12.7 30.93 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.646 0.26 . . . . 0.0 110.768 178.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 79.87 29.88 45.44 Favored Glycine 0 N--CA 1.447 -0.631 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.85 -179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 91' ' ' LEU . 8.8 mt -108.59 -19.38 13.46 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.951 0.405 . . . . 0.0 111.306 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.804 ' HA ' HG11 ' A' ' 26' ' ' VAL . 11.3 p -44.46 -55.2 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 113.532 0.938 . . . . 0.0 113.532 -178.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.586 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -57.3 -17.81 13.79 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.077 0.465 . . . . 0.0 110.167 179.225 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 1.1 m -85.58 -52.06 6.07 Favored 'General case' 0 CA--C 1.534 0.358 0 N-CA-C 113.388 0.884 . . . . 0.0 113.388 -179.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 61.1 mt -83.68 -25.0 31.06 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 -177.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.867 ' CG ' HG21 ' A' ' 26' ' ' VAL . 3.3 mtpt -68.52 -9.43 49.11 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 112.127 0.418 . . . . 0.0 112.127 -179.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -157.52 99.72 0.19 Allowed Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.138 -1.03 . . . . 0.0 112.533 -179.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -171.45 -41.45 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.914 0.388 . . . . 0.0 110.906 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 144.73 -175.14 24.57 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.498 -179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.414 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 13.2 Cg_endo -57.5 118.43 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 121.288 1.326 . . . . 0.0 110.726 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' CG1' ' A' ' 95' ' ' VAL . 1.1 m-85 -117.39 125.48 51.06 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.426 0.632 . . . . 0.0 112.308 -178.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.545 ' CG2' ' HB ' ' A' ' 96' ' ' VAL . 10.2 t -97.1 119.76 36.19 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.047 179.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.2 p -132.98 128.62 56.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 120.745 -0.382 . . . . 0.0 111.343 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.445 ' HB3' HG23 ' A' ' 149' ' ' ILE . 16.0 m-85 -78.8 88.5 4.64 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.7 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -89.95 113.39 56.92 Favored Pre-proline 0 C--N 1.326 -0.422 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.095 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.418 ' HB3' HG13 ' A' ' 149' ' ' ILE . 40.7 Cg_endo -68.37 153.69 73.62 Favored 'Trans proline' 0 C--N 1.343 0.283 0 C-N-CA 122.411 2.074 . . . . 0.0 112.824 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.525 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -86.42 155.66 20.48 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.189 179.342 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -51.89 -27.2 12.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.943 0.402 . . . . 0.0 110.459 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.3 -27.93 47.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.82 179.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -59.33 -39.51 83.38 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.888 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.685 ' CE2' HD22 ' A' ' 78' ' ' LEU . 3.3 m-85 -76.06 -38.36 57.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.012 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.15 -22.64 61.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.12 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.83 -31.62 72.68 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.733 179.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.84 HD21 HG13 ' A' ' 152' ' ' VAL . 0.6 OUTLIER -115.29 71.75 3.2 Favored Pre-proline 0 C--N 1.332 -0.194 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.918 179.561 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.413 ' O ' ' CB ' ' A' ' 72' ' ' GLU . 93.1 Cg_endo -82.27 -159.04 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 122.873 2.382 . . . . 0.0 112.385 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.413 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.0 OUTLIER 80.87 43.75 0.04 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.232 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.91 -21.02 35.85 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.784 -0.722 . . . . 0.0 113.005 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.456 HG22 HD13 ' A' ' 70' ' ' LEU . 97.8 m -74.17 -33.8 63.6 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.034 0.445 . . . . 0.0 109.822 179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 9.5 p -73.26 -39.58 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.569 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -68.03 -38.27 82.34 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 178.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -65.6 -33.81 76.77 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.269 -0.878 . . . . 0.0 108.872 177.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.685 HD22 ' CE2' ' A' ' 67' ' ' PHE . 7.2 mt -76.24 -29.6 57.59 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.089 178.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 19.1 tp -86.87 8.37 23.29 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.178 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 4.9 mtpt -91.68 145.69 31.66 Favored Pre-proline 0 C--N 1.332 -0.178 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.096 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.449 ' HA ' ' HG2' ' A' ' 84' ' ' LYS . 32.6 Cg_exo -57.52 -22.33 50.57 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.553 2.169 . . . . 0.0 112.341 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.7 pt-20 -71.04 -21.99 62.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.343 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.666 HD22 HD23 ' A' ' 78' ' ' LEU . 1.9 m120 -81.35 -32.49 32.94 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.792 0.33 . . . . 0.0 111.065 -179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.449 ' HG2' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -68.12 -40.19 82.56 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.149 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -65.9 -48.42 71.52 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.367 179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.669 ' O ' HD12 ' A' ' 90' ' ' ILE . 8.5 ptpt -58.95 -33.96 71.22 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.016 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.83 -38.27 78.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.035 179.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 21.7 m -61.17 -42.06 97.9 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.17 179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 tt0 -60.98 -38.87 87.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.457 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.681 ' O ' HG22 ' A' ' 90' ' ' ILE . 5.2 mp -98.85 12.16 5.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.53 179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.816 HD22 HD22 ' A' ' 47' ' ' LEU . 10.9 tp -54.96 -51.34 66.45 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-O 120.97 0.414 . . . . 0.0 110.586 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.877 ' O ' HG12 ' A' ' 114' ' ' VAL . 0.8 OUTLIER -50.38 -40.32 49.35 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.799 -179.855 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.471 ' HA ' ' CB ' ' A' ' 113' ' ' THR . 22.8 t80 -65.25 -28.5 69.39 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.252 0.549 . . . . 0.0 109.92 179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . . . . . . . . . 1.2 t-160 -88.34 -21.62 24.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.475 -0.784 . . . . 0.0 110.57 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' ' CE1' ' A' ' 57' ' ' PHE . 57.9 t -96.94 124.51 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.994 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.868 HG22 ' HA ' ' A' ' 113' ' ' THR . 27.3 t -139.41 114.62 8.19 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.702 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 98.4 Cg_endo -85.06 140.45 7.76 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.804 2.336 . . . . 0.0 112.98 -179.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.14 70.06 1.08 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.355 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 13.0 tp10 -121.05 141.09 51.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.87 0.367 . . . . 0.0 111.084 -179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.448 ' CG1' HD23 ' A' ' 105' ' ' LEU . 27.0 t -116.82 120.8 66.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.803 179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . 0.426 ' HE3' ' H ' ' A' ' 102' ' ' SER . 9.5 tpt -60.92 161.31 8.4 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.981 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.665 ' HB3' HD22 ' A' ' 123' ' ' LEU . 55.2 m -62.55 -44.06 97.27 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.735 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -60.79 -29.8 69.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.686 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -65.31 -48.65 72.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.422 -179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.592 HD12 ' N ' ' A' ' 106' ' ' THR . 1.2 pp -102.49 -58.48 1.87 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.801 0.334 . . . . 0.0 111.664 -179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.592 ' N ' HD12 ' A' ' 105' ' ' LEU . 0.0 OUTLIER 179.26 179.38 0.45 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.894 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 3.5 tm-20 -90.38 143.78 26.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.999 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 94.35 73.78 1.22 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.636 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 3.6 ptt? -152.2 -169.8 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.902 0.382 . . . . 0.0 110.917 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 39.1 p -140.32 170.05 16.53 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.17 0.509 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.409 ' HB2' HG21 ' A' ' 121' ' ' VAL . . . -130.42 99.46 5.01 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.41 -0.813 . . . . 0.0 111.276 -178.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . 0.479 ' O ' HG13 ' A' ' 96' ' ' VAL . 2.7 tp10 -72.99 126.85 30.93 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.883 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.868 ' HA ' HG22 ' A' ' 96' ' ' VAL . 1.7 p -88.79 143.4 26.93 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.712 179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.877 HG12 ' O ' ' A' ' 92' ' ' THR . 5.5 p -51.07 -32.27 11.88 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.155 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.457 ' CA ' ' HB ' ' A' ' 92' ' ' THR . 7.3 tt0 -61.15 -42.38 98.45 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.191 0.52 . . . . 0.0 109.717 178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 128.2 59.89 0.12 Allowed Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.455 -0.793 . . . . 0.0 112.194 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.662 ' O ' HG23 ' A' ' 113' ' ' THR . . . -156.69 129.15 2.34 Favored Glycine 0 C--N 1.33 0.196 0 C-N-CA 120.131 -1.033 . . . . 0.0 113.43 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -96.56 116.69 29.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.837 0.351 . . . . 0.0 110.84 179.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.523 HD13 ' HB2' ' A' ' 130' ' ' ASN . 1.3 pp -97.83 178.34 5.17 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.97 0.414 . . . . 0.0 111.208 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . . . . . . . . . 6.7 m -89.85 136.55 32.97 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.907 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.506 HG12 ' OG ' ' A' ' 102' ' ' SER . 28.6 t -139.19 121.2 16.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.056 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.4 t -158.75 151.89 22.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.763 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.69 ' H ' HD23 ' A' ' 123' ' ' LEU . 2.5 pt? -130.04 -41.91 1.26 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.224 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.433 ' N ' ' HG ' ' A' ' 123' ' ' LEU . 12.5 tt0 -95.1 152.83 18.0 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.925 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 67.21 25.53 73.5 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.549 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 123.76 78.29 0.39 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.45 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 76.1 Cg_exo -49.74 122.03 8.26 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.586 2.191 . . . . 0.0 112.266 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -170.07 153.76 4.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.0 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.873 ' O ' HG12 ' A' ' 132' ' ' VAL . 70.7 t -155.98 113.86 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.775 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.523 ' HB2' HD13 ' A' ' 119' ' ' LEU . 29.4 t30 49.65 26.34 1.77 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.363 -0.381 . . . . 0.0 111.137 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 96.24 13.32 49.19 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.958 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.876 HG21 ' HB ' ' A' ' 149' ' ' ILE . 5.1 p -126.03 146.31 32.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.752 0.31 . . . . 0.0 110.972 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -86.24 -10.36 54.77 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.516 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.601 HD12 HG21 ' A' ' 129' ' ' VAL . 33.9 mt 49.09 65.99 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 CA-C-O 121.135 0.493 . . . . 0.0 109.765 -178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 2.6 m -37.57 -76.11 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.33 -178.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -108.22 99.81 33.75 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.209 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . 0.662 ' O ' HG23 ' A' ' 139' ' ' VAL . 1.7 Cg_endo -81.96 102.19 1.22 Allowed 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.92 2.413 . . . . 0.0 112.115 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.65 -36.57 72.03 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.733 ' O ' HG12 ' A' ' 145' ' ' VAL . 18.0 t 68.52 -67.98 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.692 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -80.98 126.86 31.91 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.695 -179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.601 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -122.72 178.14 5.15 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.814 179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 67.5 m -74.02 -38.34 64.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.675 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -97.78 -54.87 2.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.78 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.414 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -136.05 -86.03 0.2 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.731 -179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 139' ' ' VAL . 1.7 m -145.33 157.88 13.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.864 0.364 . . . . 0.0 111.372 -179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.601 HG23 ' HB2' ' A' ' 141' ' ' ALA . 2.8 pt -148.21 126.09 3.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-O 121.029 0.442 . . . . 0.0 111.429 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.406 ' O ' ' HA ' ' A' ' 60' ' ' PHE . 27.2 m80 -127.71 125.99 41.03 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.689 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.7 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 81.3 t -79.84 142.41 13.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.295 0.569 . . . . 0.0 112.349 -178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.876 ' HB ' HG21 ' A' ' 132' ' ' VAL . 3.2 pt -110.23 134.22 53.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 114.88 -1.054 . . . . 0.0 108.977 177.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -83.84 0.77 46.15 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.368 -178.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.793 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -136.6 -147.02 5.28 Favored Glycine 0 C--N 1.332 0.343 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.628 -179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.84 HG13 HD21 ' A' ' 70' ' ' LEU . 18.6 m -124.11 144.99 31.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.789 0.328 . . . . 0.0 111.172 -179.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.794 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -148.44 -174.87 4.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.915 -179.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.582 ' HB3' HG21 ' A' ' 90' ' ' ILE . 11.3 mtm 72.47 148.03 0.12 Allowed Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.843 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.485 ' HG2' HG23 ' A' ' 90' ' ' ILE . 10.3 Cg_endo -51.72 -24.62 18.39 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.82 2.347 . . . . 0.0 112.345 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.592 ' HA3' HD13 ' A' ' 90' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.393 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.364 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.452 ' N ' ' HD2' ' A' ' 52' ' ' LYS . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.984 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.4 mt -54.22 -43.95 62.82 Favored 'Isoleucine or valine' 0 C--O 1.242 0.676 0 CA-C-O 121.996 0.903 . . . . 0.0 109.037 178.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.944 HG22 ' HG3' ' A' ' 52' ' ' LYS . 15.6 m -68.45 -32.14 54.18 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.285 178.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.739 ' O ' HG22 ' A' ' 30' ' ' THR . 0.1 OUTLIER -62.91 -18.77 63.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 115.258 -0.883 . . . . 0.0 108.88 177.576 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.969 HG22 ' HB2' ' A' ' 32' ' ' ALA . 9.1 m -72.91 -52.66 13.81 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -43.41 -44.95 6.0 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-O 120.731 0.301 . . . . 0.0 111.794 178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.739 HG22 ' O ' ' A' ' 27' ' ' GLU . 14.4 t -66.57 -27.4 67.69 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.917 0.389 . . . . 0.0 111.054 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.401 ' N ' ' O ' ' A' ' 28' ' ' THR . . . -163.88 72.53 0.19 Allowed Glycine 0 N--CA 1.452 -0.266 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.969 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -91.45 70.62 5.97 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.869 0.366 . . . . 0.0 111.775 -178.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -65.79 -6.52 30.74 Favored Glycine 0 N--CA 1.445 -0.752 0 C-N-CA 120.112 -1.042 . . . . 0.0 111.422 178.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -129.15 -14.24 4.37 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 112.044 0.386 . . . . 0.0 112.044 -179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.669 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 52.0 m-85 -138.42 47.02 1.99 Allowed 'General case' 0 CA--C 1.517 -0.317 0 CA-C-O 120.938 0.399 . . . . 0.0 111.597 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.538 ' O ' HG21 ' A' ' 40' ' ' THR . 3.6 t -77.0 -18.91 57.89 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.249 0.547 . . . . 0.0 110.508 179.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.664 HG23 HD12 ' A' ' 38' ' ' LEU . 11.4 t -88.27 -18.89 27.59 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 -179.133 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.904 HD22 ' N ' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -143.88 -39.18 0.3 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 114.906 1.447 . . . . 0.0 114.906 -178.153 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.904 ' N ' HD22 ' A' ' 38' ' ' LEU . 0.3 OUTLIER -84.14 -36.83 22.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.644 0.656 . . . . 0.0 111.557 -178.622 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 15.1 t -51.92 -29.57 20.71 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.19 0.519 . . . . 0.0 110.532 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.511 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.6 -15.63 59.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.901 -0.591 . . . . 0.0 111.106 179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -54.31 -57.04 12.75 Favored 'General case' 0 C--O 1.223 -0.292 0 CA-C-O 120.724 0.297 . . . . 0.0 111.068 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.654 ' HB2' ' HB ' ' A' ' 26' ' ' VAL . 0.0 OUTLIER -78.52 -36.09 45.35 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.442 0.639 . . . . 0.0 109.897 178.809 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.511 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -71.7 -4.28 26.58 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.209 -178.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.2 28.93 7.8 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.769 0.318 . . . . 0.0 110.496 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 61.42 32.15 79.98 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.593 -179.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.808 HD23 ' CD1' ' A' ' 51' ' ' LEU . 2.4 tp -110.47 -16.75 13.61 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.756 0.312 . . . . 0.0 111.463 -179.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.794 ' HA ' ' CG1' ' A' ' 26' ' ' VAL . 7.6 p -44.14 -61.98 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -177.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.647 ' H ' HG13 ' A' ' 48' ' ' VAL . 1.8 t0 -63.84 -17.48 63.18 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.652 -0.419 . . . . 0.0 109.942 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -85.61 -52.19 5.97 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 -178.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.808 ' CD1' HD23 ' A' ' 47' ' ' LEU . 23.5 mt -82.64 -44.01 16.26 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -177.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.984 ' CE ' HD12 ' A' ' 25' ' ' ILE . 1.3 mmtm -92.44 37.22 1.0 Allowed 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 -178.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.87 51.25 0.85 Allowed Glycine 0 N--CA 1.448 -0.545 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.312 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -152.52 -74.32 0.14 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.733 0.302 . . . . 0.0 111.71 -179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 175.28 -140.98 5.51 Favored Glycine 0 N--CA 1.444 -0.819 0 C-N-CA 120.689 -0.767 . . . . 0.0 111.641 -179.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -60.27 118.5 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.75 0 C-N-CA 121.222 1.281 . . . . 0.0 111.739 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -135.05 124.97 25.59 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.531 -179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.505 ' HB ' HG23 ' A' ' 145' ' ' VAL . 10.1 t -93.87 140.74 29.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.382 179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.914 HG13 ' CD2' ' A' ' 94' ' ' HIS . 34.7 t -146.46 121.64 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.82 0.343 . . . . 0.0 111.153 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.548 ' HB3' HD11 ' A' ' 149' ' ' ILE . 48.3 m-85 -78.67 88.66 4.56 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.503 ' HB1' HD21 ' A' ' 38' ' ' LEU . . . -105.77 113.39 63.96 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.084 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.4 ' HD2' ' HG ' ' A' ' 38' ' ' LEU . 21.0 Cg_exo -66.11 167.88 17.06 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.662 2.241 . . . . 0.0 112.402 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.542 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.3 155.87 19.87 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.65 179.759 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 8.5 p-10 -52.87 -26.15 13.82 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.861 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -77.66 -32.79 53.45 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.593 179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -62.09 -34.22 75.9 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.691 179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.912 ' CE2' HD22 ' A' ' 78' ' ' LEU . 2.8 m-85 -71.52 -46.66 59.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.703 179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.482 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.52 -20.72 60.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.859 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.56 -39.91 84.93 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.19 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 1.02 HD11 HG13 ' A' ' 152' ' ' VAL . 44.8 mt -59.0 110.48 2.69 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.046 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -80.59 -167.84 0.56 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.534 2.156 . . . . 0.0 112.311 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 61.85 36.22 16.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.916 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 58.14 25.47 57.08 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.611 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 55.2 m -74.14 -30.24 62.19 Favored 'General case' 0 CA--C 1.518 -0.276 0 CA-C-O 120.996 0.427 . . . . 0.0 109.913 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.482 HG21 ' HA ' ' A' ' 68' ' ' ALA . 9.7 p -71.25 -36.47 62.15 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 178.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -68.01 -38.47 82.63 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -67.17 -32.94 74.37 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.154 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.912 HD22 ' CE2' ' A' ' 67' ' ' PHE . 1.8 mt -76.95 -33.04 57.7 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.167 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 30.7 tp -69.95 -20.01 63.34 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.251 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.72 152.76 74.36 Favored Pre-proline 0 C--N 1.331 -0.216 0 CA-C-O 120.757 0.313 . . . . 0.0 110.869 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.05 -17.01 54.44 Favored 'Trans proline' 0 C--N 1.344 0.311 0 C-N-CA 122.563 2.175 . . . . 0.0 112.304 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 1.7 pt-20 -77.82 -7.29 56.43 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.166 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.547 ' ND2' HD23 ' A' ' 78' ' ' LEU . 5.9 t-20 -80.73 -39.74 26.48 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.877 0.37 . . . . 0.0 110.884 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -68.07 -32.86 73.49 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.0 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.604 ' O ' HG22 ' A' ' 88' ' ' THR . 7.7 mt-10 -70.94 -34.86 71.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.499 179.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.2 ttmt -77.4 -43.64 31.99 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.683 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.14 -33.18 70.58 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.656 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.768 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.9 t -76.27 -29.76 57.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.316 179.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.5 tt0 -68.62 -38.84 80.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.278 179.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.494 HG21 ' N ' ' A' ' 156' ' ' GLY . 3.7 pt -86.99 9.5 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.514 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.768 HD22 ' O ' ' A' ' 88' ' ' THR . 1.8 pt? -50.83 -40.72 56.48 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.763 0.316 . . . . 0.0 111.259 -179.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.554 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.7 OUTLIER -55.83 -22.53 25.39 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.458 -179.807 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.595 ' CE1' HD21 ' A' ' 119' ' ' LEU . 51.0 t80 -88.34 -44.26 10.92 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.733 0.301 . . . . 0.0 111.096 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.914 ' CD2' HG13 ' A' ' 59' ' ' VAL . 1.0 OUTLIER -83.35 -11.75 57.31 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.865 0.364 . . . . 0.0 110.701 179.395 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.754 ' O ' HG23 ' A' ' 114' ' ' VAL . 79.1 t -97.0 128.36 48.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.722 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 113' ' ' THR . 38.7 t -147.42 114.71 4.15 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.498 179.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -77.06 134.43 14.49 Favored 'Trans proline' 0 C--N 1.347 0.489 0 C-N-CA 122.574 2.183 . . . . 0.0 113.131 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.63 80.49 0.06 OUTLIER Glycine 0 C--N 1.331 0.254 0 C-N-CA 121.037 -0.602 . . . . 0.0 112.646 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -148.06 102.47 3.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.799 0.333 . . . . 0.0 111.163 -179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 42.1 t -85.88 134.91 26.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.407 179.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . 0.533 ' HE2' HG12 ' A' ' 121' ' ' VAL . 0.1 OUTLIER -60.79 88.63 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.794 -179.827 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.448 ' CB ' ' CG ' ' A' ' 109' ' ' MET . 0.1 OUTLIER -52.45 -22.63 4.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.88 179.804 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . 0.518 ' C ' HD21 ' A' ' 123' ' ' LEU . 0.3 OUTLIER -70.69 -32.9 70.29 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.074 0.464 . . . . 0.0 109.764 179.133 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -62.26 -19.02 62.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.065 179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.464 HD12 ' OG1' ' A' ' 106' ' ' THR . 2.2 pp -118.51 -31.48 4.89 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.55 -179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.464 ' OG1' HD12 ' A' ' 105' ' ' LEU . 0.7 OUTLIER -128.67 -179.93 5.34 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.912 0.386 . . . . 0.0 111.522 -179.815 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -104.24 149.04 25.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.653 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.05 62.89 5.57 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.533 -0.842 . . . . 0.0 111.877 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.448 ' CG ' ' CB ' ' A' ' 102' ' ' SER . 0.4 OUTLIER -84.17 154.15 23.26 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.114 0.483 . . . . 0.0 111.71 -179.159 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 27.3 p -125.67 152.43 45.24 Favored 'General case' 0 CA--C 1.516 -0.328 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.987 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -136.53 174.15 10.93 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.006 -0.543 . . . . 0.0 112.072 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -148.81 144.16 26.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.439 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.627 ' HA ' HG22 ' A' ' 96' ' ' VAL . 3.6 p -109.21 144.76 36.88 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 120.7 0.285 . . . . 0.0 111.36 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.754 HG23 ' O ' ' A' ' 95' ' ' VAL . 46.8 t -47.9 -52.56 6.59 Favored 'Isoleucine or valine' 0 C--O 1.231 0.106 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.758 179.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.406 ' CB ' ' HB ' ' A' ' 92' ' ' THR . 0.2 OUTLIER -45.41 -46.21 13.24 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.127 0.489 . . . . 0.0 110.293 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 131.98 68.97 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.581 179.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.533 ' O ' HG23 ' A' ' 113' ' ' THR . . . -163.54 137.83 4.99 Favored Glycine 0 C--O 1.229 -0.207 0 C-N-CA 120.26 -0.972 . . . . 0.0 113.194 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.17 139.77 34.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.774 0.321 . . . . 0.0 110.863 179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.595 HD21 ' CE1' ' A' ' 93' ' ' TYR . 6.1 mp -126.47 146.4 50.11 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.134 -179.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.516 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 0.7 OUTLIER -88.03 137.11 32.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.433 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.533 HG12 ' HE2' ' A' ' 101' ' ' MET . 4.8 t -133.31 132.73 58.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.431 -0.35 . . . . 0.0 111.002 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 15.1 t -144.49 169.94 16.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.051 -179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.735 HD12 ' H ' ' A' ' 124' ' ' GLU . 0.3 OUTLIER -155.98 -39.12 0.08 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.323 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.735 ' H ' HD12 ' A' ' 123' ' ' LEU . 7.3 tt0 -63.82 126.73 28.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.901 0.382 . . . . 0.0 111.202 -179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.88 33.69 86.26 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.898 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 112.56 107.05 2.85 Favored Glycine 0 CA--C 1.519 0.298 0 C-N-CA 120.495 -0.86 . . . . 0.0 112.512 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.88 150.09 54.75 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.499 2.133 . . . . 0.0 112.37 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 7.8 tttt -156.75 164.45 38.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.579 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.8 p -160.07 113.88 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.093 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 45.0 45.36 8.74 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.702 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 78.3 11.8 84.96 Favored Glycine 0 CA--C 1.518 0.274 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.936 179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.64 HG21 HD12 ' A' ' 153' ' ' LEU . 8.0 t -126.06 164.08 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 110.352 -0.24 . . . . 0.0 110.352 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.478 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -107.7 131.51 54.34 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.156 0.503 . . . . 0.0 111.612 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.477 ' O ' ' C ' ' A' ' 135' ' ' SER . 47.8 mt -87.62 68.26 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.251 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.477 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -14.46 -86.82 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.062 -0.972 . . . . 0.0 113.066 -178.585 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -129.17 95.68 30.38 Favored Pre-proline 0 C--N 1.331 -0.213 0 CA-C-O 120.638 0.256 . . . . 0.0 111.172 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . 0.506 ' O ' HG23 ' A' ' 139' ' ' VAL . 88.7 Cg_endo -89.18 115.77 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.79 2.326 . . . . 0.0 112.683 -179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.495 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -60.08 -42.16 93.99 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.984 0.421 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.663 ' O ' HG12 ' A' ' 145' ' ' VAL . 5.9 t 81.71 -28.64 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.799 179.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -112.27 79.22 1.2 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -178.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.483 ' HB3' ' HB ' ' A' ' 146' ' ' ILE . . . -175.38 178.52 1.64 Allowed 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 120.967 0.413 . . . . 0.0 111.125 179.028 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.752 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.6 OUTLIER 68.22 29.01 6.25 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.531 179.337 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.514 ' HB2' ' CE ' ' A' ' 52' ' ' LYS . 5.6 t-20 75.86 -26.61 0.19 Allowed 'General case' 0 N--CA 1.463 0.196 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -178.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.54 ' H ' ' C ' ' A' ' 142' ' ' SER . . . -128.93 -106.64 1.27 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.235 179.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.663 HG12 ' O ' ' A' ' 139' ' ' VAL . 0.0 OUTLIER -116.47 148.5 19.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.869 0.366 . . . . 0.0 110.923 178.96 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.483 ' HB ' ' HB3' ' A' ' 141' ' ' ALA . 5.4 tt -123.66 127.48 73.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 121.026 0.441 . . . . 0.0 111.491 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.47 ' HB3' HG21 ' A' ' 134' ' ' ILE . 44.5 m80 -125.29 132.78 52.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.042 179.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.542 HG11 HG23 ' A' ' 63' ' ' THR . 86.7 t -103.92 118.69 51.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 121.118 0.485 . . . . 0.0 112.265 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.581 HD13 HD13 ' A' ' 153' ' ' LEU . 14.5 mt -90.1 141.49 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -80.66 4.07 19.94 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.651 -178.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.581 ' H ' HG22 ' A' ' 149' ' ' ILE . . . -148.98 -128.31 1.68 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.632 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 1.02 HG13 HD11 ' A' ' 70' ' ' LEU . 3.5 m -123.94 145.06 31.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.764 0.316 . . . . 0.0 111.11 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.64 HD12 HG21 ' A' ' 132' ' ' VAL . 0.4 OUTLIER -140.99 -165.85 2.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.038 -179.908 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.451 ' CB ' HD12 ' A' ' 90' ' ' ILE . 0.6 OUTLIER 62.21 157.16 0.12 Allowed Pre-proline 0 C--N 1.33 -0.252 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.624 -179.844 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.406 ' HG2' ' HB ' ' A' ' 90' ' ' ILE . 9.7 Cg_endo -51.68 -24.4 17.6 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.916 2.411 . . . . 0.0 112.519 -179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.494 ' N ' HG21 ' A' ' 90' ' ' ILE . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.556 -0.831 . . . . 0.0 112.646 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.416 ' HB2' ' N ' ' A' ' 143' ' ' ASN . 7.8 t70 . . . . . 0 CA--C 1.527 0.089 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.923 ' CG2' HD22 ' A' ' 39' ' ' LEU . 2.7 mp -56.55 -42.31 75.46 Favored 'Isoleucine or valine' 0 C--O 1.243 0.719 0 CA-C-O 122.563 1.173 . . . . 0.0 109.248 178.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.858 ' HB ' HG23 ' A' ' 48' ' ' VAL . 5.2 m -65.79 -37.36 79.72 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 CA-C-N 114.335 -1.302 . . . . 0.0 108.275 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -63.5 -22.72 67.05 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 114.606 -1.179 . . . . 0.0 109.098 177.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 1.019 HG22 ' HB2' ' A' ' 32' ' ' ALA . 20.2 m -60.49 -52.95 63.02 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.469 179.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.821 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -50.92 -38.81 52.33 Favored 'General case' 0 CA--C 1.519 -0.214 0 C-N-CA 120.54 -0.464 . . . . 0.0 110.022 178.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.2 m -53.98 -24.84 18.14 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.145 178.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 175.8 72.96 0.05 OUTLIER Glycine 0 C--N 1.332 0.353 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.586 179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 1.019 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -84.57 90.2 7.61 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.714 0.292 . . . . 0.0 111.531 -178.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -80.13 43.3 2.65 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.004 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 170.3 -21.67 0.0 OUTLIER 'General case' 0 CA--C 1.531 0.22 0 CA-C-N 115.741 -0.23 . . . . 0.0 111.336 -179.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.589 ' HB2' HG21 ' A' ' 28' ' ' THR . 30.3 m-85 -115.84 33.88 5.26 Favored 'General case' 0 CA--C 1.519 -0.214 0 CA-C-O 121.215 0.531 . . . . 0.0 110.871 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.535 ' O ' HG21 ' A' ' 40' ' ' THR . 1.0 OUTLIER -68.34 -18.51 64.51 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.7 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.419 ' CG2' ' CD2' ' A' ' 67' ' ' PHE . 0.2 OUTLIER -87.83 -15.48 36.7 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -178.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.773 HD21 ' HG ' ' A' ' 87' ' ' LEU . 0.5 OUTLIER -144.85 -52.44 0.29 Allowed 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -178.171 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.923 HD22 ' CG2' ' A' ' 25' ' ' ILE . 17.1 mt -70.97 -35.37 72.11 Favored 'General case' 0 CA--C 1.509 -0.597 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.484 -177.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.821 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 11.8 t -54.77 -27.04 38.42 Favored 'General case' 0 N--CA 1.443 -0.8 0 C-N-CA 119.881 -0.727 . . . . 0.0 110.185 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.497 ' O ' ' CB ' ' A' ' 45' ' ' ALA . . . -83.91 -20.51 32.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.717 178.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.982 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.47 -57.08 12.72 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.79 0.328 . . . . 0.0 111.351 -179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.696 ' HB3' ' HB3' ' A' ' 29' ' ' ALA . 0.0 OUTLIER -78.65 -35.64 45.06 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.265 0.555 . . . . 0.0 110.21 179.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -76.14 -2.69 32.24 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.841 -178.236 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -107.53 20.61 18.64 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.775 0.321 . . . . 0.0 110.817 179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 73.08 25.44 73.5 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.734 -179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.722 HD12 ' HA ' ' A' ' 42' ' ' ALA . 0.6 OUTLIER -110.83 -8.08 14.55 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.834 0.35 . . . . 0.0 111.044 179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.858 HG23 ' HB ' ' A' ' 26' ' ' VAL . 9.7 p -44.44 -56.92 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.6 ' N ' HG13 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -69.22 -17.42 63.78 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.024 0.44 . . . . 0.0 110.031 179.011 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -85.44 -52.22 6.01 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -178.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.982 HD12 ' HB1' ' A' ' 42' ' ' ALA . 15.0 mt -62.44 -39.77 94.44 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -177.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.41 ' CD ' ' ND2' ' A' ' 143' ' ' ASN . 0.0 OUTLIER -68.2 -27.21 66.19 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 179.487 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.554 ' HA3' ' CE2' ' A' ' 57' ' ' PHE . . . 47.52 20.13 0.96 Allowed Glycine 0 CA--C 1.507 -0.428 0 CA-C-N 115.256 -0.884 . . . . 0.0 113.465 178.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 54.69 51.94 13.01 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 165.03 -175.96 40.85 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.207 -0.996 . . . . 0.0 112.632 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.412 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 32.5 Cg_exo -58.42 118.54 5.44 Favored 'Trans proline' 0 N--CA 1.456 -0.717 0 C-N-CA 121.79 1.66 . . . . 0.0 111.783 -179.759 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.554 ' CE2' ' HA3' ' A' ' 53' ' ' GLY . 0.9 OUTLIER -138.18 148.66 45.08 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.705 -0.679 . . . . 0.0 111.148 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 1.047 HG23 HG13 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -127.69 152.57 47.55 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.724 -179.612 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.739 HG13 ' CD2' ' A' ' 94' ' ' HIS . 49.1 t -153.63 127.68 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.411 -179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.824 ' HB2' HD11 ' A' ' 153' ' ' LEU . 36.3 m-85 -78.72 88.59 4.6 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.76 ' CB ' HD11 ' A' ' 39' ' ' LEU . . . -94.86 113.49 61.36 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.139 -178.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 149' ' ' ILE . 39.6 Cg_endo -67.77 161.86 42.01 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.345 2.03 . . . . 0.0 113.029 -179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.848 HG23 HG11 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -83.37 160.31 21.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.698 179.767 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -57.73 -24.22 55.89 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.563 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.02 -33.32 51.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.51 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -60.88 -42.94 98.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.575 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.726 ' CE2' HD23 ' A' ' 78' ' ' LEU . 2.0 m-85 -65.05 -42.93 93.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.53 179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.585 ' HA ' HG21 ' A' ' 75' ' ' VAL . . . -73.16 -22.46 60.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.667 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -67.93 -40.3 83.34 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.957 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.694 HD12 HD22 ' A' ' 78' ' ' LEU . 26.5 mt -54.43 108.52 1.17 Allowed Pre-proline 0 C--N 1.331 -0.225 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.066 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 91.5 Cg_endo -80.19 -170.24 0.96 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.54 2.16 . . . . 0.0 112.513 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 61.53 39.85 14.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.049 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.1 24.16 34.66 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.639 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 63.1 m -74.14 -29.93 62.03 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.585 HG21 ' HA ' ' A' ' 68' ' ' ALA . 8.7 p -71.48 -37.38 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -67.94 -38.31 82.69 Favored 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 115.308 -0.86 . . . . 0.0 108.729 178.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -68.49 -36.14 78.52 Favored 'General case' 0 N--CA 1.452 -0.346 0 CA-C-N 115.285 -0.87 . . . . 0.0 108.933 178.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.726 HD23 ' CE2' ' A' ' 67' ' ' PHE . 3.8 mp -77.18 -18.4 57.81 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.54 179.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.551 HD12 HG22 ' A' ' 75' ' ' VAL . 0.2 OUTLIER -89.9 21.65 3.52 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.124 179.786 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 26.8 mtmt -110.01 149.82 40.58 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.726 0.298 . . . . 0.0 110.836 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.01 -12.97 37.72 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.586 2.191 . . . . 0.0 112.634 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -85.65 -14.34 45.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.394 -0.367 . . . . 0.0 111.402 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.56 HD21 HD12 ' A' ' 78' ' ' LEU . 0.9 OUTLIER -80.37 -34.73 36.21 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.614 0.245 . . . . 0.0 110.921 -179.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.61 -35.34 70.32 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 88' ' ' THR . 1.0 OUTLIER -68.55 -50.53 51.19 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.729 179.019 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.65 -33.8 64.39 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.696 178.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.795 HD13 HD11 ' A' ' 90' ' ' ILE . 0.2 OUTLIER -62.98 -33.45 75.42 Favored 'General case' 0 N--CA 1.454 -0.253 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.877 179.024 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 85' ' ' GLU . 23.3 m -62.36 -35.68 79.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.764 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -63.92 -43.08 96.98 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.077 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.825 HG22 ' HB3' ' A' ' 155' ' ' PRO . 2.4 pp -97.2 12.01 4.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.834 179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.687 ' CD2' HG21 ' A' ' 95' ' ' VAL . 1.2 tt -70.09 -48.81 56.12 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.559 -179.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -41.17 -30.58 0.16 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 112.0 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.831 ' OH ' HD12 ' A' ' 119' ' ' LEU . 50.7 t80 -72.37 -47.28 50.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.789 0.328 . . . . 0.0 111.097 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.739 ' CD2' HG13 ' A' ' 59' ' ' VAL . 1.5 p-80 -75.94 -8.44 56.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.882 0.372 . . . . 0.0 110.424 179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.723 ' O ' HG23 ' A' ' 114' ' ' VAL . 43.3 t -96.65 104.79 16.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 177.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 1.047 HG13 HG23 ' A' ' 58' ' ' THR . 0.2 OUTLIER -128.3 114.96 19.93 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.174 -177.896 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.449 ' HB3' ' CZ ' ' A' ' 57' ' ' PHE . 87.1 Cg_endo -82.44 134.05 7.56 Favored 'Trans proline' 0 C--N 1.349 0.553 0 C-N-CA 122.862 2.375 . . . . 0.0 112.541 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 46.55 92.71 0.01 OUTLIER Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.896 -0.668 . . . . 0.0 112.609 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -126.84 133.51 50.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.216 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.409 HG12 ' HB3' ' A' ' 104' ' ' ASP . 23.8 t -100.16 119.66 48.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.831 179.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . 0.458 ' HE3' ' H ' ' A' ' 102' ' ' SER . 10.2 tpt -60.95 150.31 33.74 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.949 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.655 ' HB3' HD11 ' A' ' 123' ' ' LEU . 14.8 t -56.4 -44.08 79.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.992 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -64.13 -26.45 68.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.801 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.409 ' HB3' HG12 ' A' ' 100' ' ' VAL . 0.5 OUTLIER -55.03 -27.34 43.72 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.214 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -133.21 -53.4 0.9 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.881 0.372 . . . . 0.0 111.098 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -164.22 137.87 5.32 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.435 ' CG ' HD13 ' A' ' 123' ' ' LEU . 2.6 mp0 -69.51 119.17 13.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 115.97 71.96 0.49 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.672 179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . . . . . . . . . 2.0 ptt? -139.25 -170.4 2.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.914 0.387 . . . . 0.0 110.939 179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.9 p -127.05 170.02 12.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.967 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . 0.952 ' HB3' HD21 ' A' ' 119' ' ' LEU . . . -143.21 130.91 21.35 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.628 -0.715 . . . . 0.0 111.083 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 21.6 tt0 -99.71 138.12 37.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.75 HG21 ' CD2' ' A' ' 93' ' ' TYR . 2.4 p -103.75 153.07 21.11 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.206 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 95' ' ' VAL . 65.1 t -48.94 -56.42 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 115.843 -0.617 . . . . 0.0 111.308 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -45.25 -31.87 1.71 Allowed 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 121.114 0.483 . . . . 0.0 110.314 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 112.35 66.69 0.5 Allowed Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.326 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.47 ' O ' HG23 ' A' ' 113' ' ' THR . . . -152.63 133.24 3.99 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.266 -0.969 . . . . 0.0 113.158 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . 0.408 ' HA ' ' O ' ' A' ' 111' ' ' ALA . . . -107.12 123.63 48.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.663 0.268 . . . . 0.0 110.366 179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.952 HD21 ' HB3' ' A' ' 111' ' ' ALA . 0.0 OUTLIER -112.23 171.11 7.71 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.129 0.49 . . . . 0.0 111.868 -179.523 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.446 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 1.0 OUTLIER -86.04 137.17 32.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.282 179.765 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.14 127.51 57.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.124 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 9.1 t -157.02 154.63 29.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.655 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER -141.59 -170.18 3.05 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.784 179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 63.05 124.49 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.988 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 66.16 30.17 76.34 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 107.59 92.86 2.27 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -68.04 133.69 29.68 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.485 2.124 . . . . 0.0 112.337 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.19 152.54 50.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.647 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.755 HG21 HD11 ' A' ' 134' ' ' ILE . 84.8 t -153.4 113.88 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.33 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.519 ' O ' HG23 ' A' ' 132' ' ' VAL . 4.4 t30 40.9 65.51 0.79 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.884 179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 64.95 13.87 57.87 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.594 -0.812 . . . . 0.0 112.659 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.53 HG11 HG22 ' A' ' 149' ' ' ILE . 5.4 t -121.2 163.13 19.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.711 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . 0.425 ' N ' HG12 ' A' ' 132' ' ' VAL . 0.1 OUTLIER -114.38 -18.88 11.43 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.057 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.755 HD11 HG21 ' A' ' 129' ' ' VAL . 26.4 mt 59.66 62.2 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 -178.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . . . . . . . . . 8.5 m -35.29 -46.22 0.35 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.149 -0.932 . . . . 0.0 112.969 -178.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.4 tp60 -114.78 79.67 5.97 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.763 0.316 . . . . 0.0 111.487 -179.299 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 89.4 Cg_endo -89.76 112.2 0.5 Allowed 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.615 2.21 . . . . 0.0 112.577 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.462 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -95.86 -43.85 7.66 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.078 179.357 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.816 ' O ' HG13 ' A' ' 145' ' ' VAL . 9.8 t 81.93 -38.37 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.574 179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 13.9 t0 -103.01 97.25 7.38 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.898 0.38 . . . . 0.0 111.699 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.568 ' HB2' ' HB ' ' A' ' 146' ' ' ILE . . . -82.9 178.08 8.33 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.767 179.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.406 ' HB2' ' HA ' ' A' ' 24' ' ' ASP . 0.8 OUTLIER -77.13 -19.55 56.77 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.806 179.845 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.416 ' N ' ' HB2' ' A' ' 24' ' ' ASP . 53.6 t30 -141.35 29.65 1.78 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.478 179.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.411 ' C ' ' HB3' ' A' ' 141' ' ' ALA . . . 155.46 -130.26 2.74 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.318 -179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 139' ' ' VAL . 46.2 t -114.31 133.55 60.04 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 CA-C-O 121.148 0.499 . . . . 0.0 111.13 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.702 HD13 ' N ' ' A' ' 147' ' ' HIS . 0.0 OUTLIER -116.85 137.81 49.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.058 -179.202 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.702 ' N ' HD13 ' A' ' 146' ' ' ILE . 90.8 m-70 -142.22 135.17 28.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.901 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.848 HG11 HG23 ' A' ' 63' ' ' THR . 89.2 t -106.12 114.7 46.09 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.683 HD12 ' O ' ' A' ' 151' ' ' GLY . 1.1 pt -82.73 145.86 7.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -93.3 25.54 3.32 Favored 'General case' 0 C--N 1.322 -0.588 0 C-N-CA 120.587 -0.445 . . . . 0.0 111.303 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . 0.683 ' O ' HD12 ' A' ' 149' ' ' ILE . . . -165.69 -134.58 1.69 Allowed Glycine 0 C--N 1.332 0.323 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.764 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.58 HG23 HD21 ' A' ' 70' ' ' LEU . 21.5 t -102.05 145.11 12.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.066 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.824 HD11 ' HB2' ' A' ' 60' ' ' PHE . 1.5 mt -85.11 -165.11 1.11 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.848 -179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.461 ' HG3' ' CZ ' ' A' ' 93' ' ' TYR . 13.5 ptm -141.55 158.02 64.16 Favored Pre-proline 0 CA--C 1.529 0.157 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.189 -179.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.825 ' HB3' HG22 ' A' ' 90' ' ' ILE . 44.2 Cg_endo -90.39 -17.32 1.5 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 123.017 2.478 . . . . 0.0 112.452 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . 0.438 ' HA2' ' CE2' ' A' ' 93' ' ' TYR . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.508 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.541 ' HB2' ' HB3' ' A' ' 142' ' ' SER . 21.1 t70 . . . . . 0 N--CA 1.46 0.062 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.871 HD12 ' CE ' ' A' ' 52' ' ' LYS . 3.5 mt -61.35 -41.4 89.68 Favored 'Isoleucine or valine' 0 C--O 1.247 0.972 0 CA-C-O 122.026 0.917 . . . . 0.0 110.023 178.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.817 HG12 ' HG2' ' A' ' 43' ' ' GLU . 9.9 m -66.74 -19.94 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.889 178.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -21.06 65.19 Favored 'General case' 0 N--CA 1.445 -0.709 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 177.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.835 HG21 ' HB2' ' A' ' 35' ' ' PHE . 73.2 m -77.19 -53.12 8.14 Favored 'General case' 0 C--N 1.34 0.167 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.937 179.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.652 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -47.38 -33.19 5.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 120.305 -0.558 . . . . 0.0 110.662 178.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.0 m -77.23 -32.02 55.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.085 179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.489 ' O ' ' HB3' ' A' ' 32' ' ' ALA . . . -123.55 -62.81 0.2 Allowed Glycine 0 C--N 1.332 0.322 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.915 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.799 ' HA ' HG23 ' A' ' 28' ' ' THR . . . 73.02 62.23 0.1 Allowed 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 121.02 0.438 . . . . 0.0 111.359 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -84.55 -22.82 52.76 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.233 179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -141.37 6.75 1.92 Allowed 'General case' 0 CA--C 1.532 0.256 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.835 ' HB2' HG21 ' A' ' 28' ' ' THR . 20.4 m-85 -148.11 49.08 1.05 Allowed 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 121.084 0.468 . . . . 0.0 111.374 179.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 40' ' ' THR . 4.7 t -77.28 -18.85 57.22 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.122 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.492 HG21 ' CG ' ' A' ' 67' ' ' PHE . 9.0 t -88.27 -12.01 44.86 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.631 HD13 ' HZ ' ' A' ' 67' ' ' PHE . 12.5 tp -144.57 -53.94 0.32 Allowed 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 114.679 1.363 . . . . 0.0 114.679 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.8 HD22 ' CG2' ' A' ' 25' ' ' ILE . 14.6 mt -73.41 -38.33 65.62 Favored 'General case' 0 CA--C 1.512 -0.483 0 O-C-N 122.117 -0.365 . . . . 0.0 111.844 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.652 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 13.5 t -51.91 -45.0 64.07 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.143 0.497 . . . . 0.0 110.797 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.415 ' HB1' ' HB3' ' A' ' 84' ' ' LYS . . . -88.69 7.64 32.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.6 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.814 ' O ' ' HB2' ' A' ' 47' ' ' LEU . . . -75.24 -57.26 4.0 Favored 'General case' 0 CA--C 1.499 -1.003 0 CA-C-O 122.74 1.257 . . . . 0.0 109.217 179.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.817 ' HG2' HG12 ' A' ' 26' ' ' VAL . 2.7 mp0 -78.65 -43.2 26.73 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 112.153 -2.294 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -54.98 -22.09 14.07 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.145 0.498 . . . . 0.0 110.027 178.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.1 -23.2 41.42 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.892 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 129.81 19.29 1.47 Allowed Glycine 0 N--CA 1.447 -0.619 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.845 -178.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.814 ' HB2' ' O ' ' A' ' 42' ' ' ALA . 1.5 tp -96.43 -12.65 23.95 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-O 121.122 0.487 . . . . 0.0 110.107 179.05 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.774 HG13 ' HB ' ' A' ' 26' ' ' VAL . 2.1 t -43.84 -62.09 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.56 -177.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -68.31 -17.73 64.34 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.185 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.5 m -85.1 -52.2 6.11 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.903 HD13 HG21 ' A' ' 59' ' ' VAL . 20.3 mt -72.92 -52.4 14.8 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.871 ' CE ' HD12 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -105.21 37.01 2.29 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.8 0.333 . . . . 0.0 110.392 -179.29 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.78 -65.12 2.29 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.741 -0.742 . . . . 0.0 113.155 -178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -166.51 80.96 0.25 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 120.857 0.36 . . . . 0.0 111.353 -179.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 143.47 155.69 6.52 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.123 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.453 ' HA ' ' CA ' ' A' ' 144' ' ' GLY . 32.1 Cg_endo -64.69 118.34 5.33 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 C-N-CA 121.691 1.594 . . . . 0.0 111.3 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.459 ' HB2' ' NZ ' ' A' ' 52' ' ' LYS . 4.2 m-85 -119.38 133.7 55.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.274 0.559 . . . . 0.0 111.454 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.876 HG21 ' HG3' ' A' ' 99' ' ' GLU . 2.4 t -95.75 126.29 40.91 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.3 -0.864 . . . . 0.0 111.133 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.903 HG21 HD13 ' A' ' 51' ' ' LEU . 47.8 t -136.04 124.75 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.317 0 CA-C-O 120.716 0.293 . . . . 0.0 110.651 179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -78.76 88.7 4.62 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.4 -0.592 . . . . 0.0 109.4 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 148' ' ' VAL . . . -101.29 113.29 65.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.147 -179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.602 ' HD2' HD23 ' A' ' 38' ' ' LEU . 55.8 Cg_endo -70.89 165.15 33.18 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.56 2.174 . . . . 0.0 112.618 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.633 HG23 HG11 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -87.41 154.06 20.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.185 179.366 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 29.7 t0 -51.94 -28.97 18.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.057 0.455 . . . . 0.0 110.502 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.551 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -74.34 -24.01 59.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.763 179.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . . . . . . . . . . . -64.58 -52.3 58.25 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.033 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.631 ' HZ ' HD13 ' A' ' 38' ' ' LEU . 6.2 m-85 -58.2 -46.03 86.53 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.147 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -73.57 -21.75 60.25 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.497 179.358 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -68.04 -27.58 66.65 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.849 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.483 HD11 HD11 ' A' ' 78' ' ' LEU . 0.2 OUTLIER -113.88 80.78 5.46 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.83 179.76 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.77 ' HA ' HG23 ' A' ' 75' ' ' VAL . 68.7 Cg_endo -86.36 -159.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 123.157 2.572 . . . . 0.0 112.497 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.406 ' CB ' ' O ' ' A' ' 71' ' ' PRO . 0.6 OUTLIER 81.51 45.12 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.266 179.742 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 86.8 -14.34 56.62 Favored Glycine 0 C--N 1.33 0.208 0 C-N-CA 120.759 -0.734 . . . . 0.0 113.221 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -74.21 -30.89 62.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.937 0.399 . . . . 0.0 109.984 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.77 HG23 ' HA ' ' A' ' 71' ' ' PRO . 58.0 t -72.95 -37.63 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 5.1 tt0 -68.14 -39.18 82.76 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -66.72 -34.21 77.34 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.056 178.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.602 HD23 ' ND2' ' A' ' 83' ' ' ASN . 23.5 mt -77.13 -33.21 56.77 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.172 178.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . . . . . . . . . 1.9 tp -78.09 -18.2 56.02 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.155 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . . . . . . . . . 8.6 mttp -61.64 154.65 64.64 Favored Pre-proline 0 C--N 1.331 -0.22 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.967 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -65.69 -14.35 44.28 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.488 2.126 . . . . 0.0 112.308 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -76.85 -5.25 47.57 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.317 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.602 ' ND2' HD23 ' A' ' 78' ' ' LEU . 22.7 t-20 -82.63 -41.33 19.59 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.043 0.449 . . . . 0.0 110.615 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.415 ' HB3' ' HB1' ' A' ' 41' ' ' ALA . 0.0 OUTLIER -68.18 -32.0 71.94 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.225 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.648 ' O ' HG22 ' A' ' 88' ' ' THR . 15.6 mt-10 -77.63 -42.75 33.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.484 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.488 ' HG2' ' O ' ' A' ' 83' ' ' ASN . 1.3 ptmt -66.53 -39.1 88.42 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.114 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.539 HD23 ' C ' ' A' ' 87' ' ' LEU . 7.3 tt -56.12 -47.9 77.22 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.692 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.718 ' O ' HD22 ' A' ' 91' ' ' LEU . 12.8 t -66.93 -29.68 69.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.778 179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -67.71 -38.92 84.26 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.553 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.786 HG21 ' HB3' ' A' ' 154' ' ' MET . 32.4 mm -93.59 15.26 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.347 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.718 HD22 ' O ' ' A' ' 88' ' ' THR . 1.9 pt? -51.05 -39.96 57.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.897 0.38 . . . . 0.0 111.32 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.464 ' H ' HD23 ' A' ' 91' ' ' LEU . 0.8 OUTLIER -58.87 -51.04 71.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.662 -179.433 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.549 ' CD1' HG21 ' A' ' 113' ' ' THR . 79.7 t80 -66.53 -33.23 75.23 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.864 0.364 . . . . 0.0 110.934 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.665 ' CD2' HG13 ' A' ' 59' ' ' VAL . 0.0 OUTLIER -87.8 -4.92 58.84 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.018 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.815 ' O ' HG23 ' A' ' 114' ' ' VAL . 41.0 t -111.51 123.94 67.81 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.619 179.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.839 HG22 ' HA ' ' A' ' 113' ' ' THR . 24.3 t -141.35 114.83 6.87 Favored Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.716 179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo -80.1 142.97 15.7 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.555 2.17 . . . . 0.0 112.692 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 55.03 69.15 1.35 Allowed Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.377 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.876 ' HG3' HG21 ' A' ' 58' ' ' THR . 0.3 OUTLIER -90.66 131.99 36.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.957 0.408 . . . . 0.0 111.139 -179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 100' ' ' VAL . 11.6 p -112.12 109.37 28.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.525 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 7.9 tpt -60.85 142.06 56.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.747 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.686 ' HB3' HD11 ' A' ' 123' ' ' LEU . 30.8 t -50.43 -40.67 50.93 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.004 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.26 -31.02 70.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.522 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.443 ' OD2' HG23 ' A' ' 100' ' ' VAL . 14.2 t0 -48.32 -28.68 3.29 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.004 -0.543 . . . . 0.0 111.223 179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.449 HD12 HG22 ' A' ' 106' ' ' THR . 0.1 OUTLIER -130.79 -50.48 1.05 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.979 179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . 0.449 HG22 HD12 ' A' ' 105' ' ' LEU . 9.4 t -178.16 146.29 0.39 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.961 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.443 ' HG3' HD12 ' A' ' 123' ' ' LEU . 13.5 mp0 -63.82 113.11 3.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.91 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 127.51 84.4 0.47 Allowed Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.795 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.405 ' HG2' ' CB ' ' A' ' 102' ' ' SER . 2.1 ptt? -157.85 -167.66 2.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.663 0.268 . . . . 0.0 110.797 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 119' ' ' LEU . 0.8 OUTLIER -138.1 170.13 16.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.27 0.557 . . . . 0.0 111.265 -179.892 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -140.28 128.16 21.97 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.005 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -100.81 138.41 37.9 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.421 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.839 ' HA ' HG22 ' A' ' 96' ' ' VAL . 6.1 p -97.31 151.89 19.44 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.814 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.815 HG23 ' O ' ' A' ' 95' ' ' VAL . 45.6 t -47.87 -51.24 8.78 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.484 179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.417 ' HB2' ' HB ' ' A' ' 92' ' ' THR . 0.5 OUTLIER -48.32 -29.53 4.0 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.443 179.001 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 107.96 61.01 0.55 Allowed Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.247 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . -145.78 133.31 4.94 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.425 -0.893 . . . . 0.0 112.961 -179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -99.29 131.36 45.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.814 0.34 . . . . 0.0 110.807 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.465 ' O ' HG22 ' A' ' 110' ' ' THR . 4.3 pp -117.14 175.4 5.61 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.063 0.458 . . . . 0.0 111.355 -179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.452 ' O ' ' HA ' ' A' ' 129' ' ' VAL . 21.2 m -86.51 137.17 32.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.871 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.589 HG12 ' HB2' ' A' ' 102' ' ' SER . 39.1 t -136.86 116.23 15.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.156 179.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 86.2 m -163.84 153.47 14.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.98 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.686 HD11 ' HB3' ' A' ' 102' ' ' SER . 0.0 OUTLIER -135.13 -165.24 1.64 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.88 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 67.57 124.93 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.086 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 61.48 26.88 67.03 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.621 179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 115.53 103.11 2.4 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.454 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -67.41 138.23 45.61 Favored 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.312 2.008 . . . . 0.0 112.24 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -123.6 142.66 50.82 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.568 ' O ' HG13 ' A' ' 129' ' ' VAL . 13.2 p -151.28 114.1 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.963 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . . . . . . . . . 3.5 t-20 56.93 20.6 5.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.459 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 101.12 0.89 54.56 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 120.644 -0.789 . . . . 0.0 113.36 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.515 HG23 HG13 ' A' ' 129' ' ' VAL . 0.6 OUTLIER -126.02 164.14 26.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.944 0.372 . . . . 0.0 111.064 179.987 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.31 127.63 46.57 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.919 0.39 . . . . 0.0 111.511 -179.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 0.492 HD13 ' HB3' ' A' ' 147' ' ' HIS . 64.8 mt -71.55 71.61 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.965 -0.562 . . . . 0.0 109.535 178.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 134' ' ' ILE . 4.8 p -20.1 -59.66 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.825 -178.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 37.5 mm-40 -118.22 83.76 20.9 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.047 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -73.25 120.21 6.43 Favored 'Trans proline' 0 N--CA 1.462 -0.382 0 C-N-CA 122.727 2.285 . . . . 0.0 112.207 179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.418 ' CB ' HG13 ' A' ' 146' ' ' ILE . 1.7 m-20 -104.48 -41.94 5.59 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.367 179.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.804 ' O ' HG13 ' A' ' 145' ' ' VAL . 20.3 t 71.0 -54.28 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.245 179.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -99.47 104.79 16.65 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.97 0.414 . . . . 0.0 111.792 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.923 ' HB2' HG23 ' A' ' 146' ' ' ILE . . . -82.89 178.46 8.16 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.572 179.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 24' ' ' ASP . 3.3 t -68.42 -26.52 65.57 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.694 -179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.515 ' HB3' ' HE3' ' A' ' 52' ' ' LYS . 12.9 t30 -122.93 -34.92 3.1 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.789 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.453 ' CA ' ' HA ' ' A' ' 56' ' ' PRO . . . -140.34 -113.48 1.06 Allowed Glycine 0 C--N 1.332 0.353 0 C-N-CA 120.436 -0.888 . . . . 0.0 113.476 -179.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.804 HG13 ' O ' ' A' ' 139' ' ' VAL . 62.4 t -124.07 144.29 34.36 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 121.027 0.441 . . . . 0.0 111.516 -179.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . 0.923 HG23 ' HB2' ' A' ' 141' ' ' ALA . 13.1 pt -141.78 140.61 30.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.412 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.492 ' HB3' HD13 ' A' ' 134' ' ' ILE . 13.5 m170 -141.27 134.82 29.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.895 179.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.633 HG11 HG23 ' A' ' 63' ' ' THR . 68.8 t -101.95 123.51 55.2 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 1.064 HG21 HD13 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -95.37 135.12 30.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.052 177.515 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 2.6 t0 -70.6 -7.49 44.52 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.501 -179.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -136.81 -126.06 2.49 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.533 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . . . . . . . . . 13.8 t -123.95 142.34 41.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.818 0.342 . . . . 0.0 111.14 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 1.064 HD13 HG21 ' A' ' 149' ' ' ILE . 0.7 OUTLIER -122.69 -175.64 3.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.014 -179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . 0.786 ' HB3' HG21 ' A' ' 90' ' ' ILE . 2.4 mtm 62.33 148.37 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.032 179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.629 ' HG2' HD12 ' A' ' 90' ' ' ILE . 11.2 Cg_endo -52.86 157.1 8.35 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.951 2.434 . . . . 0.0 112.338 179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 -179.998 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.732 ' CG ' ' HB1' ' A' ' 141' ' ' ALA . 7.6 t70 . . . . . 0 CA--C 1.513 -0.45 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.761 HD12 ' HZ2' ' A' ' 52' ' ' LYS . 2.8 mp -70.69 -43.31 77.54 Favored 'Isoleucine or valine' 0 C--O 1.241 0.616 0 CA-C-O 122.507 1.146 . . . . 0.0 109.12 178.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 48' ' ' VAL . 3.2 t -64.66 -44.63 96.63 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 CA-C-N 113.9 -1.5 . . . . 0.0 109.149 178.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.416 ' HG3' ' O ' ' A' ' 24' ' ' ASP . 0.1 OUTLIER -57.58 -23.62 51.73 Favored 'General case' 0 N--CA 1.441 -0.883 0 CA-C-N 114.822 -1.081 . . . . 0.0 109.633 179.167 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.935 HG22 ' HB2' ' A' ' 32' ' ' ALA . 3.3 m -62.9 -52.84 61.52 Favored 'General case' 0 N--CA 1.454 -0.249 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 178.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.618 ' HA ' ' HA ' ' A' ' 40' ' ' THR . . . -45.98 -39.29 8.77 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-O 121.007 0.432 . . . . 0.0 110.929 177.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.87 -33.61 76.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -172.6 77.65 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.389 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.935 ' HB2' HG22 ' A' ' 28' ' ' THR . . . -77.21 -75.43 0.21 Allowed 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.82 -30.31 3.21 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.47 -178.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.9 m -116.41 -12.5 11.05 Favored 'General case' 0 N--CA 1.454 -0.233 0 C-N-CA 122.138 0.175 . . . . 0.0 110.829 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.826 ' HB3' ' HB2' ' A' ' 39' ' ' LEU . 41.5 m-85 -138.61 30.37 2.34 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.287 0.565 . . . . 0.0 110.73 179.388 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.533 ' O ' ' CG2' ' A' ' 40' ' ' THR . 6.8 m -61.15 -18.89 60.43 Favored 'General case' 0 N--CA 1.437 -1.078 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.994 179.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 14.2 t -88.19 -28.07 21.42 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -178.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.858 HD22 ' HG2' ' A' ' 62' ' ' PRO . 1.2 pp -134.39 -38.89 0.83 Allowed 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -177.119 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.826 ' HB2' ' HB3' ' A' ' 35' ' ' PHE . 0.1 OUTLIER -84.4 -41.19 16.94 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.636 -178.151 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.618 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 10.5 t -51.81 -30.53 23.62 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.688 0.756 . . . . 0.0 109.852 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.572 ' HA ' ' HB3' ' A' ' 44' ' ' ALA . . . -77.32 -15.23 59.51 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.367 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.656 ' HB1' HD12 ' A' ' 51' ' ' LEU . . . -54.65 -57.19 12.41 Favored 'General case' 0 C--O 1.224 -0.28 0 C-N-CA 120.792 -0.363 . . . . 0.0 111.067 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.805 ' HG2' HG22 ' A' ' 48' ' ' VAL . 0.0 OUTLIER -78.16 -30.33 49.13 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.543 0.687 . . . . 0.0 109.458 178.506 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.572 ' HB3' ' HA ' ' A' ' 41' ' ' ALA . . . -79.12 -2.95 43.07 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 115.509 -0.769 . . . . 0.0 112.008 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 41' ' ' ALA . . . -108.24 13.14 26.0 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.163 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.02 27.12 54.04 Favored Glycine 0 N--CA 1.445 -0.705 0 C-N-CA 120.162 -1.018 . . . . 0.0 111.129 -178.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 1.042 HD11 HD22 ' A' ' 91' ' ' LEU . 2.9 tp -107.79 -2.41 20.01 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 121.394 0.616 . . . . 0.0 110.193 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.805 HG22 ' HG2' ' A' ' 43' ' ' GLU . 1.6 t -43.68 -62.42 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.807 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.433 ' O ' ' HA3' ' A' ' 53' ' ' GLY . 1.4 t0 -69.36 -17.75 63.72 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.06 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.8 m -85.22 -52.09 6.16 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.732 ' CD1' HD23 ' A' ' 47' ' ' LEU . 17.1 mt -79.36 -48.63 13.72 Favored 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 112.581 0.586 . . . . 0.0 112.581 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.761 ' HZ2' HD12 ' A' ' 25' ' ' ILE . 7.7 mmpt? -112.92 30.53 7.1 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.815 0.34 . . . . 0.0 111.53 -179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.433 ' HA3' ' O ' ' A' ' 49' ' ' ASP . . . -113.44 34.65 4.93 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.281 -0.961 . . . . 0.0 112.558 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -159.82 -71.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.708 0.29 . . . . 0.0 111.723 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 179.8 -117.53 0.56 Allowed Glycine 0 N--CA 1.443 -0.844 0 C-N-CA 120.435 -0.888 . . . . 0.0 112.196 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.427 ' HA ' ' O ' ' A' ' 143' ' ' ASN . 45.6 Cg_endo -69.54 117.96 5.39 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 121.273 1.315 . . . . 0.0 112.248 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.452 ' H ' ' HA3' ' A' ' 144' ' ' GLY . 3.1 m-85 -138.07 124.85 21.07 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.279 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 96' ' ' VAL . 3.6 t -91.12 136.2 33.24 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.597 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.607 HG13 ' CD2' ' A' ' 94' ' ' HIS . 38.4 t -141.93 116.4 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 120.514 -0.474 . . . . 0.0 111.451 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -78.53 88.36 4.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 178.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.792 ' HB1' HD11 ' A' ' 38' ' ' LEU . . . -105.53 113.7 63.91 Favored Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.468 -178.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.858 ' HG2' HD22 ' A' ' 38' ' ' LEU . 25.1 Cg_endo -62.63 164.13 19.29 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.393 2.062 . . . . 0.0 112.61 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.42 ' N ' HG13 ' A' ' 148' ' ' VAL . 0.1 OUTLIER -80.1 154.73 27.89 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.8 -0.637 . . . . 0.0 110.497 179.85 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 11.6 p-10 -52.04 -25.38 8.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.92 0.39 . . . . 0.0 110.726 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 69' ' ' ALA . . . -78.45 -28.67 46.62 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.939 179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ALA . . . . . 0.537 ' HB3' ' HB2' ' A' ' 62' ' ' PRO . . . -64.12 -40.73 96.83 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.932 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PHE . . . . . 0.677 ' CD2' HD23 ' A' ' 78' ' ' LEU . 2.3 m-85 -67.61 -47.69 68.95 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.297 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -72.77 -20.05 61.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.313 179.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.515 ' HB2' ' O ' ' A' ' 65' ' ' ALA . . . -69.02 -22.92 64.04 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.012 179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.976 HD11 HD22 ' A' ' 78' ' ' LEU . 0.3 OUTLIER -111.17 76.51 1.34 Allowed Pre-proline 0 CA--C 1.529 0.155 0 CA-C-O 120.89 0.376 . . . . 0.0 110.993 179.704 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -81.19 -158.94 0.1 OUTLIER 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.967 2.445 . . . . 0.0 112.276 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 78.61 37.66 0.17 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.16 179.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 89.31 -18.58 44.68 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.933 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.596 HG22 HD13 ' A' ' 70' ' ' LEU . 87.9 m -74.1 -32.79 63.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.941 0.401 . . . . 0.0 109.961 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.689 HG22 HD12 ' A' ' 79' ' ' LEU . 10.3 p -73.06 -37.91 54.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -68.03 -37.73 81.69 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -66.83 -36.64 82.83 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.976 HD22 HD11 ' A' ' 70' ' ' LEU . 1.6 mp -77.21 -9.83 59.03 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.395 178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LEU . . . . . 0.689 HD12 HG22 ' A' ' 75' ' ' VAL . 0.5 OUTLIER -110.03 -0.91 17.88 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.466 -179.894 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' LYS . . . . . 0.485 ' O ' ' ND2' ' A' ' 83' ' ' ASN . 6.2 mmtp -80.42 147.92 65.2 Favored Pre-proline 0 CA--C 1.529 0.152 0 CA-C-O 120.772 0.32 . . . . 0.0 111.241 -179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.461 ' HA ' ' HE3' ' A' ' 84' ' ' LYS . 34.8 Cg_exo -59.91 -12.96 20.52 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.617 2.212 . . . . 0.0 113.024 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -87.81 -16.35 34.33 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -179.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.485 ' ND2' ' O ' ' A' ' 80' ' ' LYS . 11.1 p30 -70.45 -36.9 74.21 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.39 -179.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LYS . . . . . 0.461 ' HE3' ' HA ' ' A' ' 81' ' ' PRO . 0.0 OUTLIER -62.45 -34.82 77.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.854 0.359 . . . . 0.0 110.458 179.738 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 20.3 tt0 -63.3 -45.41 91.5 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.213 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . 0.435 ' HA ' ' HG2' ' A' ' 89' ' ' GLU . 0.1 OUTLIER -60.8 -45.43 94.43 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.122 179.319 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -51.8 -30.77 24.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.242 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.695 ' O ' HD23 ' A' ' 91' ' ' LEU . 6.5 m -66.89 -50.03 63.74 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.987 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.752 ' HG3' HD12 ' A' ' 90' ' ' ILE . 5.9 pt-20 -63.01 -38.86 92.89 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.77 0.319 . . . . 0.0 110.81 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ILE . . . . . 0.752 HD12 ' HG3' ' A' ' 89' ' ' GLU . 3.0 mp -89.62 -0.73 8.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.05 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 1.042 HD22 HD11 ' A' ' 47' ' ' LEU . 1.6 pp -49.83 -41.25 44.52 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.833 0.349 . . . . 0.0 111.513 -179.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.526 ' N ' HD12 ' A' ' 91' ' ' LEU . 1.5 p -69.17 -11.16 60.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.123 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . 0.711 ' O ' HG21 ' A' ' 113' ' ' THR . 17.5 t80 -91.95 -16.71 26.2 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 120.668 0.271 . . . . 0.0 111.216 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' HIS . . . . . 0.607 ' CD2' HG13 ' A' ' 59' ' ' VAL . 3.3 p-80 -118.41 2.92 11.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.94 0.4 . . . . 0.0 110.456 178.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.804 ' O ' HG23 ' A' ' 114' ' ' VAL . 78.2 t -111.59 129.76 66.39 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.75 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.777 HG22 ' HA ' ' A' ' 113' ' ' THR . 18.6 t -141.22 114.78 6.94 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.581 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_endo -77.47 140.35 19.09 Favored 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 122.556 2.171 . . . . 0.0 112.774 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 59.28 29.48 66.01 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.344 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.91 141.04 51.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.929 0.395 . . . . 0.0 111.014 -179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.528 HG13 ' O ' ' A' ' 100' ' ' VAL . 12.7 p -119.0 117.51 54.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.819 179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' MET . . . . . . . . . . . . . 4.5 tpt -60.99 143.39 55.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.92 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.473 ' CB ' HG12 ' A' ' 121' ' ' VAL . 18.2 t -49.81 -43.33 48.57 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.026 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . 0.497 ' HB3' HD13 ' A' ' 123' ' ' LEU . 17.0 p -60.06 -38.17 82.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.524 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.453 ' HB3' HD23 ' A' ' 105' ' ' LEU . 2.7 t0 -47.1 -29.71 2.37 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.124 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.453 HD23 ' HB3' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -123.15 -81.17 0.64 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.884 179.863 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.15 146.13 29.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.751 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 4.1 tm-20 -64.0 113.02 3.22 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.033 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 126.03 83.2 0.49 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.693 179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' MET . . . . . 0.602 ' HE3' HG21 ' A' ' 121' ' ' VAL . 1.4 ptt? -159.83 -172.56 3.71 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.8 0.333 . . . . 0.0 110.856 179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 p -129.66 170.14 14.17 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-O 121.242 0.544 . . . . 0.0 111.256 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . -141.17 100.37 3.79 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.089 -179.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLU . . . . . . . . . . . . . 4.4 tt0 -77.46 138.81 39.46 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.144 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.777 ' HA ' HG22 ' A' ' 96' ' ' VAL . 30.3 p -95.47 145.07 25.45 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.817 179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.804 HG23 ' O ' ' A' ' 95' ' ' VAL . 42.5 t -44.15 -55.0 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.103 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.869 179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . 0.464 ' N ' ' HB ' ' A' ' 92' ' ' THR . 27.4 tt0 -49.3 -46.78 47.04 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.261 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 134.91 62.0 0.06 OUTLIER Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.227 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.628 ' O ' HG23 ' A' ' 113' ' ' THR . . . -144.15 121.82 1.69 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.334 -0.936 . . . . 0.0 112.99 -179.713 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ALA . . . . . . . . . . . . . . . -95.7 119.27 33.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.6 179.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LEU . . . . . 0.61 HD23 ' HB2' ' A' ' 130' ' ' ASN . 5.4 mp -106.9 164.67 11.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.037 0.446 . . . . 0.0 111.414 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' THR . . . . . 0.782 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.2 m -85.98 137.14 32.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.288 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' VAL . . . . . 0.602 HG21 ' HE3' ' A' ' 109' ' ' MET . 24.6 t -127.06 119.33 52.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.291 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . . . . . . . . . 90.5 m -155.96 145.3 20.81 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' LEU . . . . . 0.497 HD13 ' HB3' ' A' ' 103' ' ' SER . 0.1 OUTLIER -132.93 -54.62 0.93 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.225 179.989 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -75.01 132.72 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.067 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 87.29 -50.25 4.06 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.482 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -154.44 81.56 0.17 Allowed Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.064 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -61.95 112.23 1.45 Allowed 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.601 2.201 . . . . 0.0 112.395 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -166.2 161.32 16.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.708 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 1.014 HG21 HD11 ' A' ' 134' ' ' ILE . 40.7 t -147.99 126.4 3.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.165 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASN . . . . . 0.61 ' HB2' HD23 ' A' ' 119' ' ' LEU . 14.3 t-20 49.15 43.09 22.33 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.109 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' GLY . . . . . . . . . . . . . . . 71.7 9.28 69.52 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.723 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.67 HG21 HD22 ' A' ' 153' ' ' LEU . 5.5 t -126.07 128.59 71.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-O 120.649 0.262 . . . . 0.0 110.841 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.64 132.0 36.12 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.094 0.473 . . . . 0.0 111.452 -179.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ILE . . . . . 1.014 HD11 HG21 ' A' ' 129' ' ' VAL . 26.1 mt -83.72 74.08 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.066 178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 134' ' ' ILE . 0.4 OUTLIER -23.5 -91.25 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 115.177 -0.92 . . . . 0.0 113.106 -178.067 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -124.62 89.8 51.78 Favored Pre-proline 0 C--N 1.333 -0.126 0 CA-C-O 120.772 0.32 . . . . 0.0 111.176 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' PRO . . . . . 0.499 ' HB3' ' CG2' ' A' ' 134' ' ' ILE . 95.4 Cg_endo -94.78 146.44 1.64 Allowed 'Trans proline' 0 N--CA 1.454 -0.808 0 C-N-CA 123.193 2.595 . . . . 0.0 112.99 -179.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . 0.482 ' C ' HG23 ' A' ' 139' ' ' VAL . 0.3 OUTLIER -80.06 -39.53 29.57 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.8 ' O ' HG12 ' A' ' 145' ' ' VAL . 7.0 t 82.38 -29.84 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.198 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.734 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -123.29 111.54 16.55 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 112.552 0.575 . . . . 0.0 112.552 -178.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ALA . . . . . 0.732 ' HB1' ' CG ' ' A' ' 24' ' ' ASP . . . -99.71 178.34 4.87 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.548 178.433 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.509 ' HB2' ' HB2' ' A' ' 24' ' ' ASP . 14.5 m -53.36 -46.94 69.78 Favored 'General case' 0 N--CA 1.462 0.126 0 C-N-CA 120.342 -0.543 . . . . 0.0 109.715 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.432 ' OD1' ' CD ' ' A' ' 52' ' ' LYS . 14.3 p-10 -135.89 80.84 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.296 178.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLY . . . . . 0.452 ' HA3' ' H ' ' A' ' 57' ' ' PHE . . . 135.99 -142.85 14.18 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 120.415 -0.897 . . . . 0.0 113.649 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.8 HG12 ' O ' ' A' ' 139' ' ' VAL . 2.0 m -134.35 149.89 30.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-O 121.26 0.552 . . . . 0.0 111.716 -179.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ILE . . . . . . . . . . . . . 14.3 tt -129.54 134.03 64.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.852 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' HIS . . . . . 0.605 ' HB3' HD13 ' A' ' 134' ' ' ILE . 22.2 m80 -137.89 115.19 11.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.691 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 61' ' ' ALA . 95.6 t -81.57 130.98 34.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.269 0.557 . . . . 0.0 112.024 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.964 HG21 HD21 ' A' ' 153' ' ' LEU . 0.7 OUTLIER -99.84 133.71 41.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.447 177.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ASP . . . . . . . . . . . . . 44.6 p30 -67.09 -12.94 61.35 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.317 -0.402 . . . . 0.0 111.3 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLY . . . . . . . . . . . . . . . -139.01 -145.26 4.73 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.406 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' VAL . . . . . 0.554 HG13 HD21 ' A' ' 70' ' ' LEU . 24.1 m -124.03 139.52 50.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 120.893 0.378 . . . . 0.0 111.304 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' LEU . . . . . 0.964 HD21 HG21 ' A' ' 149' ' ' ILE . 0.0 OUTLIER -139.32 -172.34 3.33 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.543 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER 66.68 145.2 0.1 OUTLIER Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.356 -179.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' PRO . . . . . 0.555 ' HG2' HG23 ' A' ' 90' ' ' ILE . 5.0 Cg_endo -48.32 149.62 6.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.822 2.348 . . . . 0.0 112.333 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.23 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.541 -179.67 . . . . . . . . 0 0 . 1 stop_ save_